var title_f13_46_14048="Longitudinal ultrasound scan reverberation";
var content_f13_46_14048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal ultrasound scan showing reverberation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal ultrasound scan clearly showing the needle and numerous echoes beneath, which is called reverberation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14048=[""].join("\n");
var outline_f13_46_14048=null;
var title_f13_46_14049="Adrenal hyperplasia CT";
var content_f13_46_14049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adrenal hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced CT through the upper abdomen of a 72-year-old woman demonstrates uniform enlargement of the left adrenal gland (arrow), which is maintaining its shape; similar enlargement was present in the right adrenal gland (not shown). These findings are consistent with bilateral adrenal hyperplasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14049=[""].join("\n");
var outline_f13_46_14049=null;
var title_f13_46_14050="Complete midshaft forearm fracture 2";
var content_f13_46_14050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Minimally displaced midshaft forearm fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 489px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    3-year-old with midforearm complete fracture of distal radius and ulna, with minimal displacement of radius and no angluation. This fracture was casted without reduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14050=[""].join("\n");
var outline_f13_46_14050=null;
var title_f13_46_14051="Actinic keratoses treated with 5-FU";
var content_f13_46_14051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Inflammatory response during treatment of actinic keratoses with topical 5-fluorouracil",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous inflamed macules are present on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14051=[""].join("\n");
var outline_f13_46_14051=null;
var title_f13_46_14052="Trientine: Drug information";
var content_f13_46_14052=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trientine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/23/41331?source=see_link\">",
"    see \"Trientine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Syprine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Syprine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Chelating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Wilson's disease:",
"     </b>",
"     Oral: 750-1250 mg/day in divided doses 2-4 times/day; maximum dose: 2 g/day. AASLD practice guidelines suggest typical doses of 750-1500 mg/day in 2-3 divided doses with maintenance therapy of  750-1000 mg/day (Roberts, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F230926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Wilson's disease:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;12 years: 500-750 mg/day in divided doses 2-4 times/day; maximum: 1.5 g/day. AASLD practice guidelines suggest 20 mg/kg/day rounded off to the nearest 250 mg, given in 2-3 divided doses (Roberts, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Syprine&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F230909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 1 hour before or 2 hours after meals and at least 1 hour apart from any drug, food, or milk. Do not chew capsule, swallow whole followed by a full glass of water; notify healthcare provider of any fever or skin changes; any skin exposed to the contents of a capsule should be promptly washed with water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Wilson's disease in patients intolerant to penicillamine",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Trientine may be confused with TRENtal&reg;, tretinoin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dystonia, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, thickening and fissuring of skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Iron deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, aphthoid ulcer, colitis, epigastric pain, gastritis, heartburn, loss of taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Aplastic anemia (rare), anemia, sideroblastic anemia (reversible)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Iron overload",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, muscle pain, muscular spasm, myasthenia gravis, rhabdomyolysis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Fixed drug eruption, lupus-like reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F230911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trientine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: May cause iron-deficiency anemia; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Copper deficiency: Induced by treatment; may lead to hepatic iron overload and/or sideroblastic anemia; reassess dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic worsening:  May occur with treatment initiation; less common than with penicillamine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Not reported with use; however, industrial workers exposed to trientine for prolonged periods have reported asthma, bronchitis, and dermatitis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Trientine. Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitor Diuretics: May decrease the serum concentration of Trientine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts. Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Trientine. Management: Trientine manufacturer recommends avoiding concurrent administration with oral minerals due to the risk for impaired GI absorption of both trientine and the mineral. Short courses of iron may be used; however, separate administration by at least 2 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Zinc Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13851639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food, dairy products, or other sources of polyvalent cations will be chelated by trientine. Management: Should be taken 1 hour before or 2 hours after meals and at least 1 hour apart from any drug, food, or milk.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies; fetal resorptions and abnormalities increased with decreased levels of fetal copper. Treatment of Wilson&rsquo;s disease should be maintained during pregnancy; dose reduction (25% to 50% of prepregnancy dose) should be considered (Roberts, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5661124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17930566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if trientine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering trientine to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F230914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 1 hour before or 2 hours after meals and at least 1 hour apart from any drug, food, or milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F230913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Syprine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $1673.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5661288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic 24-hour urinary copper assessment (every 6-12 months); serum non-ceruloplasmin bound copper; LFTs; CBC; periodic ophthalmic exam",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F5661283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinary copper excretion: 200-500 mcg (3-8 micromoles)/day",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F230915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Syprine (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trientine hydrochloride is an oral chelating agent structurally dissimilar from penicillamine and other available chelating agents; an effective oral chelator of copper used to induce adequate cupriuresis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5661284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: To acetyltrien (chelating activity significantly less than parent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (1% as parent; 8% as metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kodama H, Murata Y, Iitsuka T, et al, &ldquo;Metabolism of Administrated Triethylene Tetramine Dihydrochloride In Humans,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1997, 61(9):899-907.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/46/14052/abstract-text/9284083/pubmed\" id=\"9284083\" target=\"_blank\">",
"        9284083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts EA and Schilsky ML, &ldquo;Diagnosis and Treatment of Wilson Disease: An Update. American Association for Study of Liver Diseases (AASLD),&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2008, 47(6):2089-111.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/46/14052/abstract-text/18506894/pubmed\" id=\"18506894\" target=\"_blank\">",
"        18506894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walshe JM, &ldquo;Treatment of Wilson's Disease With Trientine (Triethylene Tetramine) Dihydrochloride,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8273):643-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/46/14052/abstract-text/6121964/pubmed\" id=\"6121964\" target=\"_blank\">",
"        6121964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10019 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14052=[""].join("\n");
var outline_f13_46_14052=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230917\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230918\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230930\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230920\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230926\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230921\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230907\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230895\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230909\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230908\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230937\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230928\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230911\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230899\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300173\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230903\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13851639\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230904\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823812\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661124\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17930566\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230914\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230913\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661288\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661283\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230915\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230898\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661284\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10019\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10019|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/23/41331?source=related_link\">",
"      Trientine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_46_14053="HCM anatomy PI";
var content_f13_46_14053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Heart with hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The heart on the left is normal. The heart on the right has hypertrophic cardiomyopathy. The condition causes the walls of the lower chambers of the heart (called the ventricles) to thicken.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14053=[""].join("\n");
var outline_f13_46_14053=null;
var title_f13_46_14054="Penicillin G (parenteral): Pediatric drug information";
var content_f13_46_14054=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicillin G (parenteral): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"    see \"Penicillin G (parenteral): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/23/43379?source=see_link\">",
"    see \"Penicillin G (parenteral): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pfizerpen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Crystapen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PNA &lt;7 days:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;2000 g: 50,000 units/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis: 100,000 units/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 75,000 units/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis: 150,000 units/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Congenital syphilis: 100,000 units/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Group B streptococcal meningitis: 250,000-450,000 units/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PNA &ge;7 days:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1200 g: 50,000 units/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis: 100,000 units/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200-2000 g: 75,000 units/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis: 150,000 units/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 100,000 units/kg/day in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis: 200,000 units/kg/day in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Congenital syphilis: 150,000 units/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Group B streptococcal meningitis: I.V.: 450,000 units/kg/day in divided doses every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"      see \"Penicillin G (parenteral): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &ge;1 month and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     General dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate infection: I.M., I.V.: 100,000-250,000 units/kg/day in divided doses every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe infections: 250,000-400,000 units/kg/day in divided doses every 4-6 hours; maximum dose: 24 million units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bacterial endocarditis, treatment (Baddour, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Enterococcal endocarditis (native or prosthetic valve): 300,000 units/kg/day in divided doses every 4-6 hours for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Viridans group streptococci and",
"     <i>",
"      Streptococcus bovis",
"     </i>",
"     (highly penicillin susceptible): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Native valve: 200,000 units/kg/day in divided doses every 4-6 hours for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Prosthetic valve: 300,000 units/kg/day in divided doses every 4-6 hours for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Viridans group streptococci and",
"     <i>",
"      Streptococcus bovis",
"     </i>",
"     (relatively resistant): I.V.: 300,000 units/kg/day in divided doses every 4-6 hours; duration:  Native valve: 4 weeks;  prosthetic valve: 6 weeks. Regimen should also include gentamicin (3 mg/kg/day in divided doses every 8 hours for the first 2 weeks of therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Meningitis (gonococcal): I.V.: 250,000 units/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neurosyphilis: I.V.: 200,000-300,000 units/kg/day divided every 4-6 hours for 10-14 days; maximum dose: 24 million units/day (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Syphilis (congenital): Infants: I.V.: 200,000-300,000 units/kg/day divided every 4-6 hours for 10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Actinomyces",
"     </i>",
"     species: I.V.: 10-20 million units/day divided every 4-6 hours for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Clostridium perfringens",
"     </i>",
"     : I.V.: 24 million units/day divided every 4-6 hours with clindamycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Corynebacterium diptheriae",
"     </i>",
"     : I.V.: 2-3 million units/day in divided doses every 4-6 hours for 10-12 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erysipelas: I.V.: 1-2 million units every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Erysipelothrix",
"     </i>",
"     : I.V.: 2-4 million units every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fascial space infections: I.V.: 2-4 million units every 4-6 hours with metronidazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leptospirosis: I.V.: 1.5 million units every 6 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Listeria",
"     </i>",
"     : I.V.: 15-20 million units/day in divided doses every 4-6 hours for 2 weeks (meningitis) or 4 weeks (endocarditis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lyme disease (meningitis): I.V.: 20 million units/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neurosyphilis: I.V.: 18-24 million units/day in divided doses every 4 hours (or by continuous infusion) for 10-14 days (CDC, 2006; CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Streptococcus sp.",
"     </i>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Brain abscess: I.V.: 18-24 million units/day in divided doses every 4 hours with metronidazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endocarditis or osteomyelitis: I.V.: 3-4 million units every 4 hours for at least 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnancy (prophylaxis GBS): I.V.: 5 million units x 1 dose, then 2.5-3 million units every 4 hours until delivery (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Skin and soft tissue: I.V.: 3-4 million units every 4 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Toxic shock: I.V.: 24 million units/day in divided doses with clindamycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Streptococcal pneumonia: I.V.: 2-3 million units every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Whipple's disease: I.V.: 2 million units every 4 hours for 2 weeks, followed by oral trimethoprim/sulfamethoxazole or doxycycline for 1 year",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Relapse or CNS involvement: 4 million units every 4 hours for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uremic  patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10 mL/minute:  Administer full loading dose followed by",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the loading dose given every 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer full loading dose followed by",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the loading dose given every 8-10 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution, as potassium: 1 million units (50 mL); 2 million units (50 mL); 3 million units (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as potassium: 5 million units, 20 million units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pfizerpen&reg;: 5 million units, 20 million units [contains potassium 65.6 mg (1.68 mEq) per 1 million units, sodium 6.8 mg (0.3 mEq) per 1 million units]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium: 5 million units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer by I.V. intermittent infusion over 15-60 minutes at a final concentration for administration of 100,000-500,000 units/mL. A final concentration of 50,000 units/mL infused over 15-30 minutes is recommended for neonates and infants. The potassium or sodium content of the dose should be considered when determining the infusion rate; pH: 6-7.5",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F207687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inactivated in acidic or alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Penicillin G potassium:",
"     </b>",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, hetastarch 6%;",
"     <b>",
"      incompatible",
"     </b>",
"     with dextran 70 6% in dextrose, dextran 40 10% in dextrose;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in fat emulsion 10%, peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amiodarone, caffeine citrate, cyclophosphamide, cyclosporine, diltiazem, enalaprilat, esmolol, fluconazole, foscarnet, heparin, heparin with hydrocortisone sodium succinate, hydromorphone, labetalol, meperidine, morphine, multiple vitamins, nicardipine, pantoprazole, potassium chloride, tacrolimus, theophylline, verapamil, vitamin B complex with C.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Magnesium sulfate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Metoclopramide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Penicillin G sodium:",
"     </b>",
"     Stable in dextran 40 10%;",
"     <b>",
"      incompatible",
"     </b>",
"     with fat emulsion 10%;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, peritoneal dialysis solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Levofloxacin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Chloramphenicol, cimetidine, colistimethate, dimenhydrinate, gentamicin, kanamycin, lidocaine, lincomycin, pantoprazole, polymyxin B sulfate, streptomycin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillin G potassium powder for injection should be stored below 86F (30C). Following reconstitution, solution may be stored for up to 7 days under refrigeration. Premixed bags for infusion should be stored in the freezer at or below -20C/-4F; frozen bags may be thawed at room temperature or in refrigerator. Once thawed, solution is stable for 14 days if stored in refrigerator or for 24 hours when stored at room temperature. Do not refreeze once thawed. Incompatible with aminoglycosides; inactivated in acidic or alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillin G sodium powder for injection should be stored at controlled room temperature. Reconstituted solution may be stored under refrigeration for up to 3 days.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of sepsis, meningitis, pericarditis, endocarditis, pneumonia, and other infections due to susceptible gram-positive organisms (except",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     ), some gram-negative organisms such as",
"     <i>",
"      Neisseria gonorrhoeae",
"     </i>",
"     , or",
"     <i>",
"      N. meningitidis",
"     </i>",
"     and some anaerobes and spirochetes [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Penicillin may be confused with penicillamine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F207686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma (high doses), hyper-reflexia (high doses), seizures (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte imbalance (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Pseudomembranous colitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia, positive Coombs' hemolytic anemia (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction, phlebitis, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myoclonus (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute interstitial nephritis (high doses), renal tubular damage (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions (immediate and delayed), Jarisch-Herxheimer reaction, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penicillin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment, hypersensitivity to cephalosporins, or pre-existing seizure disorder; dosage modification required in patients with renal impairment; further dosage reduction recommended in patients with impaired hepatic and renal function",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1049254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food or milk decreases absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Penicillin crosses the placenta and distributes into amniotic fluid. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Penicillin G is the drug of choice for treatment of syphilis during pregnancy and penicillin G (parenteral/aqueous) is the drug of choice for the prevention of early-onset Group B Streptococcal (GBS) disease in newborns (consult current guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic serum electrolytes, renal and hematologic function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &lt;30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Penetration across the blood-brain barrier is poor with uninflamed meninges; crosses the placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver (10% to 30%) to penicilloic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 days: 3.2-3.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7-13 days: 1.2-2.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;14 days: 0.9-1.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 0.5-1.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.5-0.75 hours with normal renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Within 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Penicillin G and its metabolites are excreted in urine mainly by tubular secretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Penicillin G potassium: 1.7 mEq of potassium and 0.3 mEq of sodium per 1 million units of penicillin G",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Penicillin G sodium: 2 mEq of sodium per 1 million units of penicillin G",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Treatment of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1988, 81(6):904-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/46/14054/abstract-text/3368290/pubmed\" id=\"3368290\" target=\"_blank\">",
"        3368290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, \"Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):e394-434.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/46/14054/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/46/14054/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, \"Prevention of Perinatal Group B Streptococcal Disease,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2010, 59(RR10)1-32.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prober CG, Stevenson DK, and Benitz WE, &ldquo;The Use of Antibiotics in Neonates Weighing Less Than 1200 Grams,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(2):111-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/46/14054/abstract-text/2179837/pubmed\" id=\"2179837\" target=\"_blank\">",
"        2179837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12687 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-677435A82C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14054=[""].join("\n");
var outline_f13_46_14054=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207660\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207661\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049245\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444110\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049238\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207638\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207622\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049248\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207687\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049242\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049247\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207689\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207686\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049251\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049237\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299838\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207631\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049254\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207634\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720623\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049244\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049236\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049250\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049252\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12687\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12687|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=related_link\">",
"      Penicillin G (parenteral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/23/43379?source=related_link\">",
"      Penicillin G (parenteral): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_46_14055="Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention";
var content_f13_46_14055=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14055/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14055/contributors\">",
"     David R Schwartz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14055/contributors\">",
"     Atul Malhotra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14055/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14055/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14055/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14055/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14055/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14055/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14055/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/46/14055/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy and the puerperium are well-established risk factors for deep vein thrombosis (DVT) and pulmonary embolism (PE), which are collectively referred to as venous thromboembolic disease (VTE). The need for thromboprophylaxis should be assessed in every woman who is pregnant or postpartum. When it is determined that thromboprophylaxis is warranted, an appropriate strategy should be selected and prescribed.",
"   </p>",
"   <p>",
"    Thromboprophylaxis can be pharmacologic (ie, anticoagulation) or mechanical (eg, graduated compression stockings). Indications for pharmacologic thromboprophylaxis are discussed in this review, along with available regimens and duration. Mechanical thromboprophylaxis is less well studied and only briefly described. We use the term thromboprophylaxis to refer to pharmacologic thromboprophylaxis. Issues concerning the use of anticoagulants in the pregnant woman are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, diagnosis, and treatment of VTE during pregnancy and the puerperium are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4805410\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of venous thromboembolism (VTE) is increased in association with pregnancy, occurring primarily during the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"     1",
"    </a>",
"    ]. This phenomenon may relate in part to the progressive increase in resistance to activated protein C that is normally observed in the second and third trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/2\">",
"     2",
"    </a>",
"    ]. Other coagulation changes that contribute to the development of VTE include: a progressive increase in several coagulation factors, such as factors I, II, VII, VIII, and X [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]; increased activity of the fibrinolytic inhibitors PAI-1 and PAI-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]; increased venous stasis; and vascular damage at the time of delivery.",
"   </p>",
"   <p>",
"    The risk during both the intrapartum and the postpartum periods appears to be accentuated in those women who have an inherited abnormality or deficiency of a naturally occurring anticoagulant, such as factor V Leiden, prothrombin G20210A, antithrombin, protein C, or protein S [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/8\">",
"     8",
"    </a>",
"    ]. In several studies, for example, the frequency of developing VTE during pregnancy or the postpartum period was at least eightfold greater in women with protein C or S deficiency, factor V Leiden, or prothrombin gene mutation G20210A than in normals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for thromboprophylaxis differ for antepartum and postpartum women. Specifically, there is a lower threshold to initiate thromboprophylaxis in postpartum women because there is no longer concern about fetal complications, the risk of VTE is higher postpartum than antepartum, and the duration of anticoagulation is generally shorter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antepartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008 and 2012 American College of Chest Physicians (ACCP) guidelines on VTE and pregnancy suggest thromboprophylaxis for pregnant women who have one or more of the following risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Single prior episode of VTE plus a higher risk thrombophilia",
"     </li>",
"     <li>",
"      Multiple prior episodes of VTE",
"     </li>",
"     <li>",
"      Antithrombin deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the benefits, risks, and burdens of thromboprophylaxis should be carefully weighed and the decision made on a case-by-case basis when the pregnant woman has one of the following risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Single prior episode of VTE that was related to pregnancy or estrogen use (eg, contraceptives)",
"     </li>",
"     <li>",
"      Single prior episode of idiopathic VTE",
"     </li>",
"     <li>",
"      Single prior episode of VTE in a patient with thrombophilia that is not considered higher risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rationale for thromboprophylaxis in pregnant women who have had a prior episode of VTE that was unrelated to an identifiable transient risk factor (eg, trauma, immobility, surgery) is that the incidence of recurrent VTE markedly increases during pregnancy. A retrospective cohort study of 159 women who had at least one pregnancy after an episode of VTE found an incidence of antepartum VTE of 6 percent among women who did not receive antepartum thromboprophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/12\">",
"     12",
"    </a>",
"    ]. This is 50 to 100 times higher than the overall incidence of antepartum VTE, which is estimated to occur in 0.6 to 1.3 of every 1000 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinical experience is the basis for the two categories of indications described above.",
"   </p>",
"   <p>",
"    Higher risk thrombophilias are those that confer the greatest risk for VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/13\">",
"     13",
"    </a>",
"    ]. According to observational studies, they include antithrombin deficiency, persistent antiphospholipid antibodies, compound heterozygosity for the prothrombin and factor V Leiden mutations, homozygosity for the prothrombin mutation, and homozygosity for the factor V Leiden mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. In contrast, examples of thrombophilias that are not considered higher risk include Protein C deficiency, Protein S deficiency, and hyperhomocysteinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombophilia is generally detected by screening patients with a personal or family history of VTE who are pregnant or planning to become pregnant. Thrombophilia is more common when the previous episode of VTE occurred during pregnancy or was idiopathic, than when the VTE episode was associated with a transient risk factor (eg, following surgery). Screening for thrombophilia is not recommended in women who lack these risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who are already receiving anticoagulant therapy for a prior episode of VTE should have their need for ongoing therapeutic anticoagulation reassessed at the beginning of the pregnancy. If it is determined that therapeutic anticoagulation is necessary, women who are receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should have their anticoagulant regimen converted to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -based regimen. Therapeutic dosing of heparin during pregnancy is discussed below. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Postpartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is generally a lower threshold for initiating thromboprophylaxis during the postpartum period, compared with during pregnancy. As a result, postpartum thromboprophylaxis is indicated for women who have had one or more episodes of VTE or who have any type of thrombophilia, even those that are not considered higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"     1",
"    </a>",
"    ]. The rationale for these indications is provided by observational studies that have shown that such women have an elevated risk of pregnancy-related VTE and this risk is higher during the puerperium than during the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1,12,16\">",
"     1,12,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cesarean section",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean section (CS) probably increases the risk of VTE, especially when performed emergently. However, observational data suggest that the level of risk for clinically important events is very modest and similar to that seen in low risk surgical patients for whom no routine thromboprophylaxis other than early ambulation is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, thromboprophylaxis is NOT recommended for women whose only risk factors for VTE are the pregnancy and CS.",
"   </p>",
"   <p>",
"    Thromboprophylaxis may be warranted for women who have risk factors for VTE in addition to the pregnancy and CS. This is based on evidence that additional risk factors increase the risk of CS-related VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"     1",
"    </a>",
"    ]. Risk factors for VTE are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ACCP guidelines for VTE and pregnancy suggest the following for women who have undergone cesarean section on basis of trials in other surgical populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who have only one additional risk factor for VTE should receive either thromboprophylaxis, graduated compression stockings, or a pneumatic compression device while in the hospital following delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"       1",
"      </a>",
"      ]. We prefer thromboprophylaxis because we believe it is supported by the highest quality evidence.",
"     </li>",
"     <li>",
"      Women who have multiple additional risk factors for VTE should receive thromboprophylaxis plus graduated compression stockings",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pneumatic compression devices while in the hospital following delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no moderate or high quality clinical trials comparing different anticoagulant regimens in pregnant or postpartum patients. A risk scoring system for determining appropriate prophylaxis in pregnant women at increased risk of VTE has been assessed in a prospective, non-randomized study, and may be worthy of future consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The regimens described here are based on trials in non-pregnant patients, observational studies in pregnant patients, and clinical experience. They are consistent with the regimens described in the 2008 ACCP guidelines on VTE in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens of subcutaneous low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (SC LMWH) include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    5000 units once daily, dalteparin 5000 units every 12 hours,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    4500 units once daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg once daily, or enoxaparin 40 mg every 12 hours.",
"   </p>",
"   <p>",
"    SC LMWH may also be prescribed in therapeutic doses if the indication for thromboprophylaxis is multiple episodes of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"     1",
"    </a>",
"    ]. Therapeutic dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    during pregnancy is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link&amp;anchor=H4#H4\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens of subcutaneous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (SC UFH) include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fixed dose: SC UFH 5000 units every 12 hours",
"     </li>",
"     <li>",
"      Adjusted dose: SC UFH initiated at 5000 units every 12 hours and then titrated to a target anti-Xa activity of 0.1 to 0.3",
"      <span class=\"nowrap\">",
"       units/mL.",
"      </span>",
"      Doses of 8000 to 10,000 units every 12 hours are generally required to achieve this target level, with a tendency toward the higher end of this range later in pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1,18,19\">",
"       1,18,19",
"      </a>",
"      ]. When titrating the SC UFH, the anti-Xa activity can be measured six hours after the second dose. Most adjustments should be an increase or decrease of 10 to 30 percent, with the anti-Xa level repeated six hours after the second injection that follows each dose adjustment. Once a stable dose is achieved, the anti-Xa activity should be measured after 3 to 4 days of treatment and then every few weeks. During the last 10 weeks of the pregnancy, more frequent monitoring is warranted. Whether such dose titration confers any benefits is controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1,19\">",
"       1,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SC UFH may also be prescribed in therapeutic doses if the indication for thromboprophylaxis is multiple episodes of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"     1",
"    </a>",
"    ]. Therapeutic dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    during pregnancy is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link&amp;anchor=H4#H4\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    can be used for postpartum thromboprophylaxis, but NOT antepartum thromboprophylaxis. It should be initiated at the same time or after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is started because warfarin alone is associated with an increased incidence of VTE. The patient should receive both warfarin and heparin for at least five days, and the heparin should not be stopped until the international normalized ration (INR) is within the therapeutic range, usually 2 to 3. Warfarin is safe during lactation because it does not accumulate in breast milk to a substantial degree [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale for overlapping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is as follows. Warfarin impairs production of the vitamin K-dependent clotting factors; thus, its anticoagulant effect is not realized until the preexisting clotting factors are cleared from the circulation, a process that requires approximately 36 to 72 hours. During the first few days of warfarin therapy, the prolonged PT reflects only the loss of factor VII (which has a half-life of only five to seven hours) and does not represent adequate anticoagulation because the intrinsic clotting pathway remains intact. It takes about five days for the activity of the intrinsic clotting pathway to be sufficiently suppressed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link&amp;anchor=H15#H15\">",
"     \"Anticoagulation in acute pulmonary embolism\", section on 'Warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choosing a regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;LMWH-based regimens are generally preferred for antepartum thromboprophylaxis for several reasons. First, LMWH is effective and safe in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/14,21-23\">",
"     14,21-23",
"    </a>",
"    ]. In a systematic review of 64 studies (2777 pregnancies), VTE occurred after the initiation of SC LMWH in fewer than 1 percent of pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/23\">",
"     23",
"    </a>",
"    ]. Antenatal bleeding and postpartum hemorrhage occurred in only 0.43 and 0.94 percent of pregnancies, respectively. Second, when directly compared with UFH in randomized trials of pregnant and non-pregnant patients, LMWH consistently proved to be more convenient, more efficacious, safer, and produced more reliable anti-Xa levels at therapeutic doses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LMWH-based regimens are also preferred for postpartum thromboprophylaxis if the patient is not opposed to subcutaneous injections because LMWH has also been shown to be more efficacious than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in other patient populations. As an example, one trial randomly assigned 1436 postoperative patients (total hip or knee replacement) to receive SC LMWH or warfarin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/26\">",
"     26",
"    </a>",
"    ]. VTE was less frequent in the SC LMWH group (31 versus 37 percent). For women who are averse to subcutaneous injections, warfarin is preferred over no thromboprophylaxis.",
"   </p>",
"   <p>",
"    The preferences described above are not relevant if the patient has severe renal failure (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    In this situation, SC UFH is preferred over SC LMWH. Elimination of UFH is both hepatic and renal, whereas elimination of LMWH is nearly entirely renal. Thus, accumulation and bleeding complications are more likely with LMWH. Renal failure is also a risk factor for bleeding in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antepartum thromboprophylaxis should be continued through the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. It is generally discontinued 24 to 36 hours prior to delivery, although there is little evidence that this affects peripartum bleeding.",
"   </p>",
"   <p>",
"    The optimal duration of postpartum thromboprophylaxis is uncertain. The 2012 ACCP Clinical Practice Guidelines suggest six weeks, for a minimum total duration of anticoagulation of three months, on the basis of clinical experience (Grade 2C suggestion) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MECHANICAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of mechanical thromboprophylaxis (eg, frequent left-lateral decubitus positioning during late pregnancy, graduated elastic compression stockings, and pneumatic compression devices) during pregnancy or the puerperium is uncertain because there is a paucity of evidence. In a study of 10 pregnant women, venous Doppler ultrasound demonstrated that graduated compression stockings increased femoral vein flow velocity during late pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of mechanical prophylaxis following cesarean section was discussed above. In the absence of cesarean section, we encourage antepartum and postpartum women with a history of VTE or risk factors for VTE to wear graduated compression stockings. This is based largely on clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"     1",
"    </a>",
"    ]. Risk factors for VTE are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    has several side effects, including bleeding, thrombocytopenia, skin necrosis, and osteoporosis. These adverse effects can occur even at prophylactic doses and are more likely with long-term use. Complications of thromboprophylaxis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy and the puerperium are well-established risk factors for deep vein thrombosis (DVT) and pulmonary embolism (PE), which are collectively referred to as venous thromboembolic disease (VTE). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antepartum indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For pregnant women with antithrombin deficiency, a single prior episode of VTE plus a higher risk thrombophilia, or multiple prior episodes of VTE, we suggest antepartum pharmacologic thromboprophylaxis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Higher risk thrombophilias include persistent antiphospholipid antibodies, compound heterozygosity for the prothrombin and factor V Leiden mutations, homozygosity for the prothrombin mutation, and homozygosity for the factor V Leiden mutation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antepartum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women with a single prior episode of VTE related to pregnancy or estrogen, a single prior episode of idiopathic VTE, or a single prior episode of VTE plus thrombophilia that is not considered higher risk, the need for antepartum pharmacologic thromboprophylaxis should be determined on a case-by-case basis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antepartum'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Postpartum indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For postpartum women who have a higher risk thrombophilia or have had one or more prior episodes of VTE, we suggest pharmacologic thromboprophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Postpartum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postpartum women who have lower risk thrombophilia (eg, heterozygosity for factor V Leiden or the prothrombin 20210A mutation), no prior episodes of VTE, and no family history of VTE, we suggest postpartum clinical vigilance rather than pharmacologic prophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women who underwent cesarean section and have risk factors for VTE other than the pregnancy and cesarean section, we suggest pharmacologic thromboprophylaxis while they are hospitalized (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). When multiple risk factors exist, it is preferable to use both pharmacologic thromboprophylaxis and mechanical thromboprophylaxis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cesarean section'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Regimen",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most pregnant women, we suggest a low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH)-based regimen, rather than an unfractionated heparin (UFH)-based regimen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most postpartum women who are willing to receive subcutaneous injections, we suggest a LMWH-based regimen, rather than an UFH- or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -based regimen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most postpartum women who are unwilling to receive subcutaneous injections, we suggest a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -based regimen, rather than no pharmacologic thromboprophylaxis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An UFH-based regimen should be used instead of a LMWH-based regimen if a patient has severe renal insufficiency (creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antepartum pharmacologic thromboprophylaxis should be continued until delivery. We suggest that postpartum pharmacologic thromboprophylaxis be continued for six weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/1\">",
"      Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:844S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/2\">",
"      Walker MC, Garner PR, Keely EJ, et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/3\">",
"      Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/4\">",
"      McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/5\">",
"      Hellgren M, Blomb&auml;ck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest 1981; 12:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/6\">",
"      Kruithof EK, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/7\">",
"      Gerbasi FR, Bottoms S, Farag A, Mammen E. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol 1990; 75:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/8\">",
"      Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/9\">",
"      Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/10\">",
"      Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/11\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/12\">",
"      Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/13\">",
"      Roeters van Lennep JE, Meijer E, Klumper FJ, et al. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemost 2011; 9:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/14\">",
"      Duhl AJ, Paidas MJ, Ural SH, et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197:457.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/15\">",
"      Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/16\">",
"      Lim W, Eikelboom JW, Ginsberg JS. Inherited thrombophilia and pregnancy associated venous thromboembolism. BMJ 2007; 334:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/17\">",
"      Dargaud Y, Rugeri L, Vergnes MC, et al. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. Br J Haematol 2009; 145:825.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin 19. ACOG 2000; Washington, DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/19\">",
"      Barbour LA. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997; 24:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/20\">",
"      Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002; 100:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/21\">",
"      van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; :CD001100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/22\">",
"      Pettil&auml; V, Kaaja R, Leinonen P, et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999; 96:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/23\">",
"      Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/24\">",
"      Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/25\">",
"      Rosenberg VA, Lockwood CJ. Thromboembolism in pregnancy. Obstet Gynecol Clin North Am 2007; 34:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/26\">",
"      Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14055/abstract/27\">",
"      Norgren L, Austrell C, Nilsson L. The effect of graduated elastic compression stockings on femoral blood flow velocity during late pregnancy. Vasa 1995; 24:282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1347 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14055=[""].join("\n");
var outline_f13_46_14055=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4805410\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antepartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Postpartum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cesarean section",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choosing a regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DURATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MECHANICAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antepartum indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Postpartum indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_46_14056="Urinary tract injury in gynecologic surgery: Prevention";
var content_f13_46_14056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urinary tract injury in gynecologic surgery: Prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14056/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14056/contributors\">",
"     Donna Gilmour, MD, FRCSC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14056/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14056/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14056/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14056/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14056/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/46/14056/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reproductive and urinary tracts in women are closely related anatomically and embryologically [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/1\">",
"     1",
"    </a>",
"    ]. Knowledge of this anatomy plays an important role in the prevention of urinary tract injury during gynecologic surgery. The primary approach to prevention is careful surgical dissection and knowledge of the position of urinary tract structures within the surgical field.",
"   </p>",
"   <p>",
"    The prevention of urinary tract injury in gynecologic surgery, primarily hysterectomy, will be reviewed here. The evaluation and management of urinary tract injury in gynecologic surgery, urinary tract injuries during advanced procedures performed for urinary incontinence, pelvic organ prolapse, or gynecologic malignancy, as well as during obstetric procedures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=see_link\">",
"     \"Radical hysterectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link\">",
"     \"Cesarean delivery: Technique\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall rate of urinary tract injury associated with pelvic surgery in women is approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/2\">",
"     2",
"    </a>",
"    ]. Bladder injury is more common than ureteral injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the exact incidence of these injuries is difficult to ascertain. Reported rates vary depending primarily on the approach to diagnosis of injury and the type of surgery; other factors include patient characteristics and study design.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Injury diagnosed with cystoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Markedly higher rates of urinary tract injuries have been reported in studies in which cystoscopy was routinely performed immediately after the procedure rather than other approaches to diagnosis (typically intraoperative visual inspection). This was illustrated in a systematic review of 47 retrospective studies and two subsequent prospective studies of urinary tract injury during benign gynecologic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. For hysterectomy, studies that used routine cystoscopy found, compared to studies that used other techniques, higher rates of ureteral injury (15 to 18 versus 0.2 to 7 per 1000 procedures) and bladder injury (17 to 29 versus 0.3 to 6 per 1000 procedures).",
"   </p>",
"   <p>",
"    These findings demonstrate that injuries are underreported when routine cystoscopy is not performed immediately after the procedure. The true incidence is probably higher since cystoscopy does not detect all injuries, particularly partial ureteral obstruction or transection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. On the other hand, some injuries detected with cystoscopy may be asymptomatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heal spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ]. Clinical use of cystoscopy in the diagnosis of operative urinary tract injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link&amp;anchor=H7#H7\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\", section on 'Cystoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical approach is another major determinant of the rate of urinary tract injury. In studies of hysterectomy in which cystoscopy was routinely performed, the rates of ureteral injury per 1000 procedures for each approach were [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/1,3,4,8\">",
"     1,3,4,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal &mdash; ureter: 3 to 22; bladder: 9 to 25",
"     </li>",
"     <li>",
"      Vaginal &mdash; ureter: 14 to 26; bladder: 6 to 63",
"     </li>",
"     <li>",
"      Laparoscopic &mdash; ureter: 0 to 15; bladder: 1 to 33",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data for laparoscopic hysterectomy include both laparoscopic-assisted vaginal and total laparoscopic hysterectomy. Since the approach to urinary tract dissection differs between these two procedures and the data also do not include robotic-assisted laparoscopy, further study is needed to distinguish the risk of urinary tract injury for these latter approaches to surgery.",
"   </p>",
"   <p>",
"    The rate of injury from adnexal surgery was 1.0 per 1000 procedures in a study using data from a Canadian national health database [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery for urinary incontinence or pelvic organ prolapse or for malignancy has a higher rate of urinary tract injury than other procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/2\">",
"     2",
"    </a>",
"    ]. Rates of injury associated with repair of pelvic organ prolapse or urinary incontinence range from 26 to 80 per 1000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/6,7,9-13\">",
"     6,7,9-13",
"    </a>",
"    ]. The rate of ureteral injury during radical hysterectomy ranges from 3 to 37 per 1000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cesarean delivery was complicated by bladder injury in 1 to 3 per 1000 primary procedures and 6 to 8 per 1000 repeat procedures in studies of over 7000 cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for urinary tract injury in pelvic surgery are based upon characteristics of the patient or procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patient characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient risk factors that impact urinary tract complications are conditions that distort pelvic anatomy, obscure tissue planes, make visualization of urinary tract structures difficult, or make the urinary tract more vulnerable to injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior pelvic surgery",
"     </li>",
"     <li>",
"      Endometriosis",
"     </li>",
"     <li>",
"      Urinary tract abnormalities (eg, duplicated ureter, pelvic kidney)",
"     </li>",
"     <li>",
"      History of pelvic irradiation",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Large pelvic mass",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regarding prior pelvic surgery, prior cesarean delivery or laparotomy was associated with the following rates of bladder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ureteral injury in studies of hysterectomy with 1000 or more women; the rates are compared to patients who had not previously undergone these procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior cesarean delivery &mdash; 2.9 to 4.7 versus 0.7 to 1.1 percent",
"     </li>",
"     <li>",
"      Previous laparotomy &mdash; 2.1 versus 0.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endometriosis appears to be associated with an increase in the rates of ureteral, but not bladder injury. Endometriosis commonly distorts pelvic anatomy and tissue planes with adhesive disease, but rarely invades the ureteral wall [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/19\">",
"     19",
"    </a>",
"    ]. In the largest study regarding ureteral injury, among 1163 women who underwent supracervical hysterectomy for benign disease, three of the four ureteral injuries were in the 22 women with endometriosis (13.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, reported rates of bladder injury during hysterectomy have been similar for women with versus without endometriosis (0.9 versus 1.0 to 1.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data that quantify the risk of urinary tract injury in women with a history of pelvic irradiation, urinary tract abnormalities, obesity, or a large pelvic mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Procedural factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract injury occurs almost exclusively in major gynecologic surgery that involves surgical dissection in proximity to the ureters or bladder. Minor procedures (eg, hysteroscopy) or tubal surgery are rarely associated with this type of complication.",
"   </p>",
"   <p>",
"    Procedural risk factors involve the indication and type of procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/1-4,6,7,9-14\">",
"     1-4,6,7,9-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgery for malignancy",
"     </li>",
"     <li>",
"      Advanced pelvic reconstructive surgery",
"     </li>",
"     <li>",
"      Laparoscopic hysterectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are inconsistent regarding whether characteristics of the individual procedure (surgeon assessment of operative difficulty, operative duration, volume of blood loss) are associated with urinary tract injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Increasing experience of the surgeon has correlated with a decrease in the frequency of urinary tract injury in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/18\">",
"     18",
"    </a>",
"    ]. Other reports vary regarding whether participation by surgical trainees increases the risk of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ureters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pelvic ureters are retroperitoneal structures that run from the renal pelvis to the bladder and can be injured during pelvic surgery at any point along their distal course (",
"    <a class=\"graphic graphic_figure graphicRef76515 \" href=\"UTD.htm?43/47/44790\">",
"     figure 1",
"    </a>",
"    ). The pelvic course of the ureters and most common sites of injury from superior to inferior can be summarized as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ureters enter the pelvis at the pelvic brim where they cross from lateral to medial, and anterior to the bifurcation of the common iliac arteries. At this point, the ureter runs just medial to the ovarian vessels (",
"      <a class=\"graphic graphic_picture graphicRef51215 \" href=\"UTD.htm?39/21/40287\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The ureters then descend into the pelvis within a peritoneal sheath (ureteric fold) attached to the medial leaf of the uterine broad ligament and the lateral pelvic sidewall (",
"      <a class=\"graphic graphic_figure graphicRef76698 \" href=\"UTD.htm?13/34/13859\">",
"       figure 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_figure graphicRef64999 \" href=\"UTD.htm?15/44/16069\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Just inferior to the internal cervical os, the ureter passes under the uterine arteries in the cardinal ligament through a tunnel of areolar tissue to the anterolateral surface of the cervix (",
"      <a class=\"graphic graphic_figure graphicRef76515 \" href=\"UTD.htm?43/47/44790\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef57777 \" href=\"UTD.htm?26/20/26948\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The ureters then pass close to the anterolateral fornix of the vagina and enter the posterior aspect of the bladder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bladder is positioned anterior to the vagina, cervix, and lower uterine segment. The vesicouterine fold, or pouch, is a reflection of the anterior peritoneum that lays between the dome of the bladder and the lower uterine segment. The base is opposed to the cervix and vagina with the vesicocervical and vesicovaginal fascia.",
"   </p>",
"   <p>",
"    The bladder is divided into the dome superiorly and the base inferiorly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. The base contains the trigone, including the ureters, which enter posteriorly, and the urethra, which exits at the most inferior aspect of the bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mechanisms of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many ways the lower urinary tract can be compromised during or after surgery. Potential mechanisms of intraoperative ureteral injury include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Crushed with a clamp",
"     </li>",
"     <li>",
"      Kinked or ligated with a suture or staple",
"     </li>",
"     <li>",
"      Lacerated or transected during sharp or blunt dissection or while using an energy source",
"     </li>",
"     <li>",
"      Devascularization or denervation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thermal damage from electrosurgery or other energy sources, such as laser or harmonic scalpel, is becoming a more frequent cause of injury to the urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The expected thermal spread from devices ranges from 2 to 22 mm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of electrosurgery\", section on 'Thermal spread'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanisms of intraoperative bladder injury include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cystotomy",
"     </li>",
"     <li>",
"      Laceration of the bladder wall with or without or breaching the bladder lumen",
"     </li>",
"     <li>",
"      Devascularization or denervation",
"     </li>",
"     <li>",
"      Accidental placement of an intravesical suture or staple",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An intravesical suture may be symptomatic or asymptomatic, depending upon the location of the",
"    <span class=\"nowrap\">",
"     suture/staple",
"    </span>",
"    in the bladder and coincident infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stone formation.",
"   </p>",
"   <p>",
"    Postoperatively, physiologic and pathologic processes can cause or exacerbate an injury to the urinary tract. These include edema, inflammation, hematoma, infection, abscess formation, ischemia, or necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sequelae of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential consequences of lower urinary tract injury include ureteral obstruction (resulting in hydronephrosis and possible irreversible injury which, if bilateral, can lead to renal failure), genitourinary fistula, and urinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When urinary tract injury presents postoperatively, genitourinary fistulas are the most common complication (74 of 76 in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/32\">",
"     32",
"    </a>",
"    ]. Fistulas are more often associated with hysterectomy, particularly radical hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link&amp;anchor=H2#H2\">",
"     \"Urogenital tract fistulas in women\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     APPROACH TO PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of urinary tract injury is a central principle of pelvic surgery. There are three levels for prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary &mdash; avoiding urinary tract injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary prevention is optimal. The most important method for primary prevention is intraoperative identification of the bladder and ureters and avoidance of injury through meticulous surgical technique. In addition, preoperative identification and evaluation are used to select appropriate patients for placement of prophylactic ureteral catheters (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Prophylactic ureteral catheters'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary &mdash; intraoperative recognition and repair of injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When injuries do occur, prompt intraoperative diagnosis and management help to avoid sequelae such as ureteral obstruction and ureterovaginal or vesicovaginal fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/34\">",
"     34",
"    </a>",
"    ]. This is accomplished through surgeon inspection of pedicle and urinary tract structures and awareness of potential signs of injury (eg, urine in the operative field). Routine use of cystoscopy is another option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link&amp;anchor=H2#H2\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\", section on 'Intraoperative evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tertiary &mdash; postoperative diagnosis and treatment of urinary tract injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative evaluation and preparation are focused on preventing operative urinary tract injury. A more general discussion of preoperative assessment for gynecologic surgery is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling about the risk of urinary tract injury is part of the informed consent process prior to pelvic surgery. This discussion should be documented in the medical record and on the consent form.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important elements of the history are prior pelvic surgery, radiation, or infection and known or suspected endometriosis. Congenital anomalies of the urinary tract (eg, duplicated ureters, pelvic kidney) may be suspected if there is a personal or family history of congenital anomalies of the urinary tract or reproductive tract, since these abnormalities often coexist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast studies of the ureters may be useful in patients with known or suspected urinary tract anomalies. Preoperative imaging with computed tomography urography may be helpful in demonstrating structural abnormalities in the urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OPERATIVE SET-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positioning of the patient in the dorsal lithotomy rather than supine position will give better access for evaluation of the urinary tract with cystoscopy or other methods that require access to the urethra. For abdominal surgery, one option that will avoid having to reposition the patient during surgery is to position the patient in lithotomy stirrups that can adjust from a low to high position (eg, Yellofin&reg;). Self-retaining retractor that does not interfere with the thighs (eg, Bookwalter&trade;) must be used when the patient is in lithotomy position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bladder catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of a bladder (Foley) catheter may be helpful in procedures in which there is a potential for urinary tract injury. If there is an increased risk of injury, a triple lumen (three-way) catheter can be used, which will allow instillation of contrast material if bladder injury is suspected. Persistent blood-tinged urine in the catheter output should prompt evaluation for urinary tract injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prophylactic ureteral catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Universal use of prophylactic ureteral catheters is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. A randomized trial that assigned 3141 women with no prior pelvic surgery who were undergoing major gynecologic surgery to bilateral ureteral catheters versus no stents found no difference in the incidence of ureteral injury (1.2 versus 1.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ureteral catheters are potentially helpful for selected women with known or suspected periureteral fibrosis or scarring, such as those with severe endometriosis or prior pelvic irradiation. For these difficult cases, prophylactic ureteral catheters are placed in the operating room prior to the initial incision. Ureteral catheters are placed via a cystoscope by an experienced clinician. Ureteral catheters allow the surgeon to easily palpate the ureters prior to applying clamps or ligating pedicles proximal to the ureters. This avoids the need for extensive ureterolysis to identify the ureters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OPERATIVE TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important principle for prevention of urinary tract injury is to develop and divide tissue planes to identify and isolate the structures of the lower urinary tract before operating on other pelvic structures. Anatomic variation and pelvic pathology may obscure tissue planes, thereby increasing the risks of an injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Avoiding ureteral injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mechanism of ureteral injury is accidental ligation or transection while operating on other structures. Identification of the ureter at each step in a procedure avoids injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/23\">",
"     23",
"    </a>",
"    ]. The highest risk of denervation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    devascularization is during ureterolysis; therefore, removal of all tissue surrounding the ureter should be avoided during gynecologic surgery performed for benign indications.",
"   </p>",
"   <p>",
"    During oophorectomy or hysterectomy, the steps of the procedure in which the ureter is most likely to be injured are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ligation of the ovarian vessels",
"     </li>",
"     <li>",
"      Ligation of the uterine vessels",
"     </li>",
"     <li>",
"      Closure of the angles of the vagina cuff",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common site of ureteral injury is the distal ureter at the level of the uterine arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/3,38\">",
"     3,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Ligation of the ovarian vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid ureteral injury when the ovarian vessels are ligated during oophorectomy, there are several methods of identifying the ureter: opening the retroperitoneum to visualize the ureter directly, visualizing the ureter through the peritoneum, and palpating the ureter. There are no high quality data regarding which method is associated with a lower risk of ureteral injury. However, opening the retroperitoneum and visualizing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palpating the ureter prior to isolating, clamping, and ligating the ovarian vessels is the method that best ensures accurate identification and protection of the ureter.",
"   </p>",
"   <p>",
"    During a vaginal approach to oophorectomy, the ureter is more difficult to visualize and is protected by clamping the ovarian vessels as close as possible to the ovary.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opening the retroperitoneum abdominally &mdash; The following sequential steps are performed when opening the retroperitoneum abdominally (",
"      <a class=\"graphic graphic_figure graphicRef76515 \" href=\"UTD.htm?43/47/44790\">",
"       figure 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ligate and divide the round ligament to create an opening in the broad ligament [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/25,39\">",
"       25,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Palpate the external iliac artery. Continue using blunt dissection to open the broad ligament lateral to the external iliac artery and lateral and parallel to the ovarian vessels (which are within the infundibulopelvic ligament). Limit use of energy sources in close proximity to the ureter. As noted above, the expected thermal spread from devices ranges from 2 to 22 mm (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Mechanisms of injury'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Expose the external iliac artery and vein.",
"     </li>",
"     <li>",
"      Dissect out the ureter from the surrounding tissue as it crosses over the vessels and is adherent to the medial leaf of the broad ligament. Visualization of peristalsis confirms that the ureter has been identified. Take care to avoid disrupting the vascular supply of the ureter, which may result in ischemia and necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visualization or palpation &mdash; When visualization through the peritoneum or palpation, rather than opening the retroperitoneum, is used to identify the ureter, it may be mistaken for other structures. During laparoscopy, visualization of the ureter is reasonable when the peritoneum is translucent and the ureter can be clearly seen. When this method is used, visualization of peristalsis confirms identification of the ureter. In contrast, palpation of the ureter is often misleading, since many structures can have the same consistency as the ureter. In circumstances in which the ureter cannot be visualized (eg, bleeding in operative field), however, we use palpation to attempt to identify the ureter. The ureter has a \"rubber-band\"-like consistency and should snap when pulled gently; the ureter does not pulsate when palpated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Ligation of the uterine arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the level of the uterine arteries, the uterine vessels are skeletonized before ligation to visualize the ureter (",
"    <a class=\"graphic graphic_figure graphicRef76698 \" href=\"UTD.htm?13/34/13859\">",
"     figure 2",
"    </a>",
"    ). If the vessels have been isolated, it is not required to completely dissect out the ureter. When placing a clamp prior to ligating the vessels, care must be taken that only the vessels are included in the clamp. Perhaps more importantly, mobilizing the bladder from the anterior cervix and displacing it inferiorly will also shift the ureters inferior to the uterine arteries prior to clamping.",
"   </p>",
"   <p>",
"    The ureters pass below the uterine vessels, and once these vessels are ligated, the ureter will pass just inferior and lateral to this pedicle. Thus, to protect the ureter during subsequent dissection of the cardinal ligament, the clamp is placed medial to the uterine artery pedicle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Vaginal cuff closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ureters enter the bladder posteriorly, along its interface with the anterior vaginal wall (",
"    <a class=\"graphic graphic_figure graphicRef64999 \" href=\"UTD.htm?15/44/16069\">",
"     picture 2",
"    </a>",
"    ). Thus, care must be taken during closure of the vaginal cuff to avoid both the ureters and bladder. As the bladder is dissected off the surface of the vagina or cervix and displaced inferiorly, the ureters will descend with the bladder to a level safely below the superior aspect of the cuff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Avoiding bladder injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the bladder may occur while dissecting the bladder away from the lower uterus, cervix, and upper vagina during hysterectomy. This tissue plane is usually easy to find and dissect, whether a hysterectomy is being performed from a laparoscopic, abdominal, or vaginal approach. However, one or more previous cesarean deliveries may cause fibrosis and scarring. In this setting, there is increased difficulty in dissecting the tissue plane with a higher risk of bladder injury.",
"   </p>",
"   <p>",
"    We use sharp dissection with or without electrosurgery, whether the dissection is easy or difficult. Blunt dissection may result in increased bleeding or tearing of the bladder. Bladder injury that occurs with sharp, rather than blunt, dissection can often be easier to repair.",
"   </p>",
"   <p>",
"    In laparoscopic surgery, injury to the bladder usually occurs during secondary trocar insertion. Bladder injury can be avoided by placement of the secondary trocar under direct visualization and by making certain that the bladder is emptied before trocar placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications of gynecologic laparoscopic surgery\", section on 'Urinary tract injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Identifying a pelvic kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pelvic kidney, which occurs in from 1 in 500 to 1 in 3000 individuals, may be encountered during gynecologic surgery. They are usually unilateral, retroperitoneal, irregular in shape, and may occur anywhere below the pelvic brim. The blood supply is invariably anomalous, often with branches coming from the aorta, common, external or internal iliac vessels, and vessels may come from both sides of the pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of an unsuspected pelvic kidney is important so as not to damage it or its blood supply. During surgery, the presence of a retroperitoneal mass or anomalous ureteral anatomy suggests the presence of a pelvic kidney. During laparotomy, identification of a pelvic kidney can be made by palpating the abdominal retroperitoneum to confirm that there is no abdominal kidney, and then by identifying the ureter which exits the pelvic kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14056/abstract/41\">",
"     41",
"    </a>",
"    ]. Intraoperative sonography may also be used to identify a pelvic kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary tract injury associated with pelvic surgery in women occurs in approximately 1 percent of procedures. For hysterectomy, rates of ureteral injury range from 0 to 3 percent and of bladder injury from 0.6 to 6 percent of procedures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for urinary tract injury include: prior pelvic surgery, endometriosis, urinary tract abnormalities, surgery for malignancy, and surgery for urinary incontinence or pelvic organ prolapse. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with known or suspected urinary tract anomalies, we suggest a preoperative imaging study of the ureters. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary tract injury may occur through direct contact with a surgical instrument, a suture or a stapling device, or as a result of devascularization or denervation. Potential consequences of lower urinary tract injury include ureteral obstruction (resulting obstructive nephropathy), genitourinary fistula, or urinoma. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most women undergoing gynecologic surgery, we recommend not using prophylactic ureteral catheters (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest use of prophylactic ureteral catheters for women with severe endometriosis or a history of pelvic irradiation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prophylactic ureteral catheters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important principle for prevention of urinary tract injury is to develop and divide tissue planes to identify and isolate the structures of the lower urinary tract before operating on other pelvic structures. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Operative technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During oophorectomy or hysterectomy, the most common site of ureteral injury is the distal ureter at the level of the uterine arteries; other steps of the procedure associated with injury to the ureter are ligation of the ovarian vessels and vaginal cuff closure. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Operative technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During oophorectomy, at the level of the ovarian vessels, if the ureter can be clearly visualized through the retroperitoneum, opening the retroperitoneum is not routinely required. If the ureter cannot be clearly visualized, we suggest opening the retroperitoneum (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest not using palpation as the sole method of identifying the ureter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Attempting to identify the ureter through palpation alone may be required when the ureter cannot be visualized.",
"     </li>",
"     <li>",
"      During hysterectomy, at the level of the uterine arteries, the uterine vessels are skeletonized and the bladder dissected off the anterior cervix and displaced inferiorly prior to clamping the vessels. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ligation of the uterine arteries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During hysterectomy, at the level of the vaginal cuff, the bladder is dissected off the surface of the vagina or cervix and displaced inferiorly to protect the ureters and bladder from injury prior to cuff closure. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Vaginal cuff closure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/1\">",
"      Gilmour DT, Das S, Flowerdew G. Rates of urinary tract injury from gynecologic surgery and the role of intraoperative cystoscopy. Obstet Gynecol 2006; 107:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/2\">",
"      Bai SW, Huh EH, Jung da J, et al. Urinary tract injuries during pelvic surgery: incidence rates and predisposing factors. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/3\">",
"      Ibeanu OA, Chesson RR, Echols KT, et al. Urinary tract injury during hysterectomy based on universal cystoscopy. Obstet Gynecol 2009; 113:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/4\">",
"      Vakili B, Chesson RR, Kyle BL, et al. The incidence of urinary tract injury during hysterectomy: a prospective analysis based on universal cystoscopy. Am J Obstet Gynecol 2005; 192:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/5\">",
"      Brubaker L. Is routine cystoscopy an essential intraoperative test at hysterectomy? Obstet Gynecol 2009; 113:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/6\">",
"      Gilmour DT, Baskett TF. Disability and litigation from urinary tract injuries at benign gynecologic surgery in Canada. Obstet Gynecol 2005; 105:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/7\">",
"      Gustilo-Ashby AM, Jelovsek JE, Barber MD, et al. The incidence of ureteral obstruction and the value of intraoperative cystoscopy during vaginal surgery for pelvic organ prolapse. Am J Obstet Gynecol 2006; 194:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/8\">",
"      Brummer TH, Jalkanen J, Fraser J, et al. FINHYST, a prospective study of 5279 hysterectomies: complications and their risk factors. Hum Reprod 2011; 26:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/9\">",
"      Jabs CF, Drutz HP. The role of intraoperative cystoscopy in prolapse and incontinence surgery. Am J Obstet Gynecol 2001; 185:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/10\">",
"      Tulikangas PK, Weber AM, Larive AB, Walters MD. Intraoperative cystoscopy in conjunction with anti-incontinence surgery. Obstet Gynecol 2000; 95:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/11\">",
"      Shoemaker ES, Wilkinson PD. Teloscopy after bladder neck suspension. J Am Assoc Gynecol Laparosc 1998; 5:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/12\">",
"      Pettit PD, Petrou SP. The value of cystoscopy in major vaginal surgery. Obstet Gynecol 1994; 84:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/13\">",
"      Harris RL, Cundiff GW, Theofrastous JP, et al. The value of intraoperative cystoscopy in urogynecologic and reconstructive pelvic surgery. Am J Obstet Gynecol 1997; 177:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/14\">",
"      Mendez LE. Iatrogenic injuries in gynecologic cancer surgery. Surg Clin North Am 2001; 81:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/15\">",
"      Rahman MS, Gasem T, Al Suleiman SA, et al. Bladder injuries during cesarean section in a University Hospital: a 25-year review. Arch Gynecol Obstet 2009; 279:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/16\">",
"      Phipps MG, Watabe B, Clemons JL, et al. Risk factors for bladder injury during cesarean delivery. Obstet Gynecol 2005; 105:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/17\">",
"      Neumann G, Rasmussen KL, Lauszus FF. Peroperative bladder injury during hysterectomy for benign disorders. Acta Obstet Gynecol Scand 2004; 83:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/18\">",
"      Lafay Pillet MC, Leonard F, Chopin N, et al. Incidence and risk factors of bladder injuries during laparoscopic hysterectomy indicated for benign uterine pathologies: a 14.5 years experience in a continuous series of 1501 procedures. Hum Reprod 2009; 24:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/19\">",
"      Shirk GJ, Johns A, Redwine DB. Complications of laparoscopic surgery: How to avoid them and how to repair them. J Minim Invasive Gynecol 2006; 13:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/20\">",
"      Jung SK, Huh CY. Ureteral injuries during classic intrafascial supracervical hysterectomy: an 11-year experience in 1163 patients. J Minim Invasive Gynecol 2008; 15:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/21\">",
"      Juillard C, Lashoher A, Sewell CA, et al. A national analysis of the relationship between hospital volume, academic center status, and surgical outcomes for abdominal hysterectomy done for leiomyoma. J Am Coll Surg 2009; 208:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/22\">",
"      Leung PL, Tsang SW, Yuen PM, Quality Assurance Subcommittee in Obstetrics and Gynaecology, Hospital Authority, Hong Kong. An audit on hysterectomy for benign diseases in public hospitals in Hong Kong. Hong Kong Med J 2007; 13:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/23\">",
"      Sorinola O, Begum R. Prevention and management of ureteric injuries. Hosp Med 2005; 66:329.",
"     </a>",
"    </li>",
"    <li>",
"     DeLancey J. Surgical anatomy of the female pelvis. In: Te Linde's Operative Gynecology, 10th, Rock JA, Thompson JD (Eds), Lippincott-Raven, 1997. p.82.",
"    </li>",
"    <li>",
"     Underwood P. Operative injuries to the ureter. In: Te Linde's Operative Gynecology, 10th, Rock JA, Thompson JD (Eds), Lippincott-Raven, 1997. p.960.",
"    </li>",
"    <li>",
"     Netter, FH. Atlas of Human Anatomy, Ciba-Geiby Corporation, New Jersey, 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/27\">",
"      Donnez O, Jadoul P, Squifflet J, Donnez J. A series of 3190 laparoscopic hysterectomies for benign disease from 1990 to 2006: evaluation of complications compared with vaginal and abdominal procedures. BJOG 2009; 116:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/28\">",
"      L&eacute;onard F, Fotso A, Borghese B, et al. Ureteral complications from laparoscopic hysterectomy indicated for benign uterine pathologies: a 13-year experience in a continuous series of 1300 patients. Hum Reprod 2007; 22:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/29\">",
"      Lee RA, Symmonds RE, Williams TJ. Current status of genitourinary fistula. Obstet Gynecol 1988; 72:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/30\">",
"      Tancer ML. Observations on prevention and management of vesicovaginal fistula after total hysterectomy. Surg Gynecol Obstet 1992; 175:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/31\">",
"      Sakellariou P, Protopapas AG, Voulgaris Z, et al. Management of ureteric injuries during gynecological operations: 10 years experience. Eur J Obstet Gynecol Reprod Biol 2002; 101:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/32\">",
"      Gilmour DT, Dwyer PL, Carey MP. Lower urinary tract injury during gynecologic surgery and its detection by intraoperative cystoscopy. Obstet Gynecol 1999; 94:883.",
"     </a>",
"    </li>",
"    <li>",
"     Thompson, JD. Operative injuries to the ureter:prevention, recognition, and management. In: TeLinde's Operative Gynecology, Rock, JA, Thompson, JD, (Eds), Lippincott-Raven, Philadelphia 1997. p.1135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/34\">",
"      Visco AG, Taber KH, Weidner AC, et al. Cost-effectiveness of universal cystoscopy to identify ureteral injury at hysterectomy. Obstet Gynecol 2001; 97:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/35\">",
"      Schimpf MO, Gottenger EE, Wagner JR. Universal ureteral stent placement at hysterectomy to identify ureteral injury: a decision analysis. BJOG 2008; 115:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/36\">",
"      Tanaka Y, Asada H, Kuji N, Yoshimura Y. Ureteral catheter placement for prevention of ureteral injury during laparoscopic hysterectomy. J Obstet Gynaecol Res 2008; 34:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/37\">",
"      Chou MT, Wang CJ, Lien RC. Prophylactic ureteral catheterization in gynecologic surgery: a 12-year randomized trial in a community hospital. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/38\">",
"      Hove LD, Bock J, Christoffersen JK, Andreasson B. Analysis of 136 ureteral injuries in gynecological and obstetrical surgery from completed insurance claims. Acta Obstet Gynecol Scand 2010; 89:82.",
"     </a>",
"    </li>",
"    <li>",
"     Baggish, MS. Anatomy of the tretroperitoneum and the presacral space. In: Atlas of Pelvic Anatomy and Gynecologic Surgery, 2nd ed. Baggish, MS, Karram, MM (Eds), Elsevier Saunders, Philadelphia 2006. p. 349.",
"    </li>",
"    <li>",
"     Retik, AB, Vaughn, ED, Wein, AJ. Campbell's urology. Retik, AB, Vaughn, ED, Wein, AJ (Eds), Saunders, Phiadelphia 2002. p. 3373.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14056/abstract/41\">",
"      Bader AA, Tamussino KF, Winter R. Ectopic (pelvic) kidney mimicking bulky lymph nodes at pelvic lymphadenectomy. Gynecol Oncol 2005; 96:873.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3318 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14056=[""].join("\n");
var outline_f13_46_14056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Injury diagnosed with cystoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type of procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patient characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Procedural factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ureters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sequelae of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      APPROACH TO PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OPERATIVE SET-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bladder catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prophylactic ureteral catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OPERATIVE TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Avoiding ureteral injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Ligation of the ovarian vessels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Ligation of the uterine arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Vaginal cuff closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Avoiding bladder injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Identifying a pelvic kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3318\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3318|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/47/44790\" title=\"figure 1\">",
"      Identifying ureter at hysterect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/34/13859\" title=\"figure 2\">",
"      Ureter and uterine artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/20/26948\" title=\"figure 3\">",
"      Ureter entering bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/44/16069\" title=\"picture 2\">",
"      Ureter and blood vessels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3318|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/21/40287\" title=\"picture 1\">",
"      Ureteral course",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=related_link\">",
"      Cesarean delivery: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=related_link\">",
"      Complications of gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=related_link\">",
"      Radical hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_46_14057="Evaluation of the child with joint pain or swelling";
var content_f13_46_14057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the child with joint pain or swelling",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14057/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14057/contributors\">",
"     Yukiko Kimura, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14057/contributors\">",
"     Taunton R Southwood, MD, FRACP, FRCPA, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14057/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14057/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14057/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/46/14057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint pain and swelling are common manifestations of many musculoskeletal and rheumatologic diseases. As a result, the differential diagnosis of childhood joint pain and swelling is large and includes both benign and serious conditions. The assessment of a child with joint pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    swelling needs to differentiate between conditions of varying severity, especially those that require urgent medical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of a child with joint pain or swelling will be reviewed here. Although there is overlap among the causes of limping, hip pain, and joint swelling and pain, the causes and approaches to assessing a child with limp",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hip pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=see_link\">",
"     \"Approach to the child with a limp\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=see_link\">",
"     \"Overview of the causes of limp in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link\">",
"     \"Overview of hip pain in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of childhood joint pain or swelling is broad, ranging from benign to serious conditions, some of which can have devastating consequences (eg, septic arthritis) (",
"    <a class=\"graphic graphic_table graphicRef57734 \" href=\"UTD.htm?23/29/24029\">",
"     table 1",
"    </a>",
"    ). The categories of possible disease that may present with joint pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    swelling are included in the following mnemonic, ARTHRITIS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avascular necrosis and epiphyseal disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of hip pain in childhood\", section on 'Legg-Calv&eacute;-Perthes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link&amp;anchor=H21#H21\">",
"       \"Slipped capital femoral epiphysis (SCFE)\", section on 'Osteonecrosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reactive and postinfectious arthritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Trauma: Accidental and nonaccidental, including hypermobility associated with microtrauma",
"     </li>",
"     <li>",
"      Hematologic: Leukemia, bleeding diatheses, and hemoglobinopathies",
"     </li>",
"     <li>",
"      Rickets, metabolic and endocrine disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"       \"Overview of rickets in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infection: septic arthritis and osteomyelitis, as well as other types of infections such as Lyme arthritis and Parvovirus-associated arthritis. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"       \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link\">",
"       \"Musculoskeletal manifestations of Lyme disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"       \"Specific viruses that cause arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"       \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tumor: Musculoskeletal neoplasia (eg, osteosarcoma), lymphoma, and neuroblastoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Idiopathic pain syndromes, such as complex regional pain syndrome type 1 and fibromyalgia. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromyalgia in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=see_link\">",
"       \"Complex regional pain syndrome in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Systemic rheumatologic diseases (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"       \"Systemic lupus erythematosus in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"       \"Classification of juvenile arthritis (JRA/JIA)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Note that the group of diseases incorporated under the grouping of juvenile idiopathic arthritis (JIA) does not appear on this differential diagnosis list. The diagnosis of JIA requires the exclusion of all the above diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history and physical examination are the initial steps in determining the diagnosis of a child with joint pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    swelling. The history needs to differentiate between benign and pathologic conditions, especially those that require urgent medical attention, and helps direct a focus for the physical examination and diagnostic studies.",
"   </p>",
"   <p>",
"    The important elements of the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain characterization including the site, number of joints involved, severity, frequency, duration and pattern of pain. The characterization of swelling is also important and includes many of the same elements as those for pain as well as the presence of associated findings of warmth and discoloration.",
"     </li>",
"     <li>",
"      Presence of precipitating factors, such as a history of trauma.",
"     </li>",
"     <li>",
"      Review of systems focusing on the presence of fever, rash, weight loss, abdominal pain, and ocular abnormalities.",
"     </li>",
"     <li>",
"      Other medical conditions associated with arthritis or arthralgias. These include celiac disease, inflammatory bowel disease, chronic lung or cardiac disease with hypoxia, uveitis, psoriasis, and cystic fibrosis.",
"     </li>",
"     <li>",
"      Family history. Psoriasis, hypermobility syndromes, inflammatory bowel disease, spondyloarthropathies, uveitis and bony dysplasias are important to ask about in close relatives, as these conditions have a genetic basis and may be associated with arthritis in the child. The likelihood that joint pain is due to an autoimmune condition is increased if multiple members of the patient's family have suffered from autoimmune diseases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immune deficiency syndromes. The health and medical history of the patient's siblings may also be informative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pain, swelling, and stiffness characterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain and swelling are characterized by their location, severity, frequency, duration, and factors that either exacerbate or relieve the finding (",
"    <a class=\"graphic graphic_table graphicRef78083 \" href=\"UTD.htm?42/12/43211\">",
"     table 2",
"    </a>",
"    ). Joint stiffness is also a common feature, but like pain is subjective and may be difficult to quantify.",
"   </p>",
"   <p>",
"    The following questions help to characterize the child's joint pain and swelling:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How severe is the pain, swelling, or stiffness?",
"     </li>",
"     <li>",
"      What is the location of the pain, stiffness or swelling?",
"     </li>",
"     <li>",
"      How many joints are involved?",
"     </li>",
"     <li>",
"      When and for how long have the joint(s) been painful, stiff, or swollen?",
"     </li>",
"     <li>",
"      How quickly did the pain, swelling, or stiffness appear?",
"     </li>",
"     <li>",
"      What makes the pain, swelling, or stiffness better or worse?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the severity or intensity of pain or stiffness should be assessed, one must be careful not to equate severity of pain or stiffness with severity of illness because the perception of pain is subjective. However, pain severe enough to cause the child to refuse to put any weight on the affected limb is a \"red flag\" for serious illness, such as bacterial infection of the joint or bone (eg, septic arthritis and osteomyelitis) or malignancy (eg, leukemia and osteosarcoma). In contrast, juvenile idiopathic arthritis (JIA), Legg-Calv&eacute;-Perthes disease, slipped capital femoral epiphysis, Osgood-Schlatter disease, and transient synovitis are often associated with limping, but the pain is generally not severe enough for a child to refuse to bear weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=see_link\">",
"     \"Approach to the child with a limp\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Young children and infants may have difficulty articulating the presence of pain and may not complain of joint pain even when there are obvious signs of joint inflammation and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/2\">",
"     2",
"    </a>",
"    ]. In cases that involve the lower extremities, the young child may manifest pain as a refusal to walk or walking with a limp, and in those that involve the upper extremities, the patient may limit the movement and use of the involved arm.",
"   </p>",
"   <p>",
"    In an adolescent who complains of excruciating pain, often accompanied by inability to walk, but does not seemed to be particularly bothered by the problem (\"la belle indifference\"), a pain disorder such as complex regional pain syndrome type 1 (CRPS) or fibromyalgia may be the likely diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=see_link\">",
"     \"Complex regional pain syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain that wakes a child in the middle of the night is generally severe and is a useful diagnostic clue, as it is more commonly seen in patients with bony pain due to relatively benign tumors such as osteoid osteoma, or malignancies, such as leukemia. Although other benign conditions such as growing pains also occur typically at night, these children are always entirely well during the day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=see_link\">",
"     \"Growing pains\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant joint symptoms are likely to interfere with daily activities, such as walking long distances, participating in sports or physical education, and playing instruments. Involvement of the small hand joints may interfere with writing, the ability to button clothes, and opening jars and bottles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Location and number of involved joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the site(s) of the",
"    <span class=\"nowrap\">",
"     pain/swelling",
"    </span>",
"    is important to develop a rational list of differential diagnoses, and to direct subsequent evaluation and treatment.",
"   </p>",
"   <p>",
"    It may be challenging to have children localize pain accurately, especially younger children. Children should be asked to tell or to point to the painful area(s). For the nonverbal child, family members are asked what led them to think that the child has a joint problem and whether they noted any unusual warmth or swelling of the joint(s).",
"   </p>",
"   <p>",
"    There is overlap between causes of monoarticular and polyarticular pain and swelling (",
"    <a class=\"graphic graphic_table graphicRef57734 \" href=\"UTD.htm?23/29/24029\">",
"     table 1",
"    </a>",
"    ). However, it is important to determine the number of involved joints because infection is a relatively common cause of acute pain and swelling in a single joint, which can result in cartilage destruction within a few days if not treated. As a result, patients with monoarticular involvement need to be assessed urgently to ensure that therapy can be initiated as quickly as possible in those suspected of having a bacterial infection as the cause of their symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single joint involvement &mdash; Bacterial infections (eg, septic arthritis and osteomyelitis) and significant trauma (eg, fracture or hemarthroses) are important causes of pain in a single joint that must be considered without delay, as discussed above. Other common causes of monoarticular pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swelling include osteonecrosis (ie, Legg-Perthes disease), oligoarticular JIA, Lyme arthritis, and some cases of reactive arthritis.",
"     </li>",
"     <li>",
"      Multiple joint involvement &mdash; As bacterial infection and significant trauma rarely affect multiple joints, there is less urgency to evaluate a child with polyarticular involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/3\">",
"       3",
"      </a>",
"      ]. Causes of multiple joint pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swelling include connective tissue disorders such as systemic lupus erythematosus (SLE), JIA, and inflammatory bowel disease associated arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Frequency, duration, and pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain and swelling can be characterized based upon their frequency, duration, and pattern:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent, intermittent and migratory",
"      <span class=\"nowrap\">",
"       pain/swelling",
"      </span>",
"      &mdash; Persistent pain is characteristic of inflammation of the joint space commonly seen in patients with arthritis that is due to infection or a rheumatologic disorder, or bony pain due to a neoplastic process.",
"      <br/>",
"      <br/>",
"      Intermittent pain, particularly associated with activity, is more likely due to a mechanical problem (eg, meniscal or ligamentous injury of the knee, and rotator cuff impingement disorder in the shoulder). In addition, recurrent pain and swelling of one or two large joints followed by spontaneous resolution, particularly in the knees, is characteristic of Lyme arthritis.",
"      <br/>",
"      <br/>",
"      Migratory joint pain is pain that lasts for several days in one or more joints and then resolves, while other, previously unaffected, joints become painful. It can be seen in patients with acute rheumatic fever or post-streptococcal reactive arthritis, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), and childhood leukemia or lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Time of day &mdash; Diurnal variation is an important distinguishing feature of many different causes of joint pain that aids in identifying the underlying diagnosis. Joint pain due to arthritis, such as JIA, is usually worse at the beginning of the day and improves throughout the day with movement and activity, In contrast, pain due to trauma or mechanical causes (eg, hypermobility, torn meniscus, patellofemoral syndrome or Legg-Calve-Perthes disease) is usually mild or nonexistent in the morning and worsens with activity, or may only occur after increased physical activity. Growing pains typically occur in a well child, with pain that may affect the joint usually beginning at the end of the day and into the middle of the night, but not during the daytime [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/4\">",
"       4",
"      </a>",
"      ]. Although bone tumors can cause nocturnal pain, the child also has pain during the day. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of hip pain in childhood\", section on 'Legg-Calv&eacute;-Perthes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=see_link\">",
"       \"Growing pains\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link\">",
"       \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acuity of onset &mdash; Rapid onset of findings within one or two days is often associated with septic arthritis, osteomyelitis and vasculitis (such as Henoch Sch&ouml;nlein Purpura), whereas many of the other causes of childhood joint pain and swelling are more insidious.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other joint symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a warm or red joint indicates inflammation of the joint (arthritis). These findings increase the concern for an infectious or inflammatory cause for joint pain and swelling. Locking or \"giving way\" of the joint are suggestive of a mechanical joint disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors may be associated with the initiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    worsening of joint symptoms. Their presence may be helpful in determining the possible cause of joint symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Antecedent trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma may be the direct cause of joint pain, as with fractures or ligamentous injuries, or indirect, as with some cases of osteomyelitis. Judging the degree of trauma, and determining the temporal relation between the trauma and the child's presentation are important in deciding whether trauma can be the cause or a contributing factor to a child's joint symptoms. In a significant traumatic injury, the precipitating event is usually associated with the immediate onset of pain, swelling, and sometimes bruising. In some cases, however, an episode of minor trauma may simply bring to attention a preexisting, but as yet undiagnosed and unrelated, condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Antecedent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recent infections, especially with enteric pathogens (Salmonella, Shigella, Yersinia and Campylobacter), viruses (eg, parvovirus B19 and varicella), Group A Streptococcus, and immunization (eg, rubella immunization), may be associated with reactive arthritis, a common cause of acute arthritis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, the arthritis of acute rheumatic fever (ARF), a sequel of a group A streptococcal pharyngeal infection, typically occurs two weeks after the precipitating infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reactive arthritis is broadly defined as an arthritis which developed soon after or during an infection elsewhere in the body, but in which the microorganisms cannot be recovered from the joints. In the In the most restricted definition, reactive arthritis has been used to refer to the triad of postinfectious arthritis, urethritis, and conjunctivitis, formerly called Reiter syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Inactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint pain or stiffness that is worsened by periods of inactivity (called articular or inactivity gelling) is typical of chronic inflammatory arthritis, such as seen in some cases of JIA or SLE. An important question to ask is whether the child appears stiff in the morning with gradual resolution or improvement during the day's activity. Some parents will volunteer that their child \"looks like an old man\" after getting up in the morning. Very young children may simply be irritable upon awakening and ask to be carried until they feel better. Affected children may have similar",
"    <span class=\"nowrap\">",
"     complaints/findings",
"    </span>",
"    later in the day after a nap, a period of inactivity (such as a long car ride), or even sitting at a desk in class.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Increased physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with mechanical causes of joint pain, such as hypermobility syndrome, patellofemoral syndrome, and osteochondroses, will often have pain that is significantly worse or only occurs after increased physical activity. Growing pains are also often reported to be more frequent after an active day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=see_link\">",
"     \"Clinical manifestations and treatment of the hypermobility syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the young athlete with chronic knee pain or injury\", section on 'Patellofemoral dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of the causes of limp in children\", section on 'Apophysitis (formerly osteochondrosis)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=see_link\">",
"     \"Growing pains\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of fever narrows the differential diagnosis significantly. If there has been a history of fever it is important to ascertain the timing and pattern of fever, and the height of elevated temperature.",
"   </p>",
"   <p>",
"    Fever may precede or present at the same time as joint symptoms in children whose disease is due to bacterial infection. High fever (temperature greater than 38&ordm; C) in a patient with monoarticular disease is typical of a bacterial infection of the joint or bone. However, subacute or partially treated infection may not be accompanied by significant fever. Fever may also have been present during an antecedent illness that preceded the development of reactive arthritis. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Antecedent infection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever is also associated with noninfectious diseases including JIA, Kawasaki disease, vasculitis, and SLE. In some conditions, the pattern of fever may be an important clue to the diagnosis as demonstrated in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic JIA is associated with a quotidian fever pattern. A daily spike of high fever often occurs in the afternoon or evening with a return to normal temperature between spikes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link&amp;anchor=H5#H5\">",
"       \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\", section on 'Fever'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Periodic fever syndromes, such as familial Mediterranean fever, have a characteristic pattern of intermittent episodes of fever. These last for a few days or longer, resolve spontaneously, and give way to weeks of normal temperature. During the febrile episodes, patients may have joint pain and swelling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"       \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The fever in patients with SLE has a gradual onset and is typically low-grade and intermittent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"       \"Systemic lupus erythematosus in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Review of systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough review of systems detects the presence of other symptoms that may aid in the identification of the correct diagnosis. Clinical features, such as rash, weight loss, abdominal pain, and eye abnormalities, in combination with joint findings are suggestive of specific diseases based upon pattern recognition (",
"    <a class=\"graphic graphic_table graphicRef56247 \" href=\"UTD.htm?25/22/25965\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities detected by the physical examination are important clues to the diagnosis and help differentiate severe conditions requiring urgent medical intervention from more benign disorders.",
"   </p>",
"   <p>",
"    In addition to a thorough general examination, a complete musculoskeletal examination includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General appearance including measurement of growth parameters and vital signs.",
"     </li>",
"     <li>",
"      Special attention to the heart, lung, skin, and eyes, as these organ systems are often affected in children with joint pain or swelling. In many cases, abnormalities of these organs may suggest an underlying etiology.",
"     </li>",
"     <li>",
"      Screen of the entire musculoskeletal system with a focused examination of the painful or swollen joint(s).",
"     </li>",
"     <li>",
"      Evaluation of motor strength (both proximal and distal) as neuromuscular conditions and inflammatory myopathies may be accompanied by joint symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Performing a meticulous pediatric musculoskeletal examination, especially in young children, requires a patient and persistent approach. It may even take more than one session to complete if the child is fractious. Without a thorough and systematic examination, however, subtle signs of critical importance to the diagnosis of the condition may be missed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general inspection of the patient should determine whether the child is ill or well appearing. Height and weight measurements are compared to reference ranges and prior values. A change in the patient's growth curve or recent weight loss may be indicative of a serious pathologic disorder, such as systemic-onset or polyarticular JIA, systemic lupus erythematosus, inflammatory bowel disease, or a malignancy (eg, leukemia). On the other hand, persistent complaints associated with weight gain may be a sign of a pain syndrome, such as fibromyalgia.",
"   </p>",
"   <p>",
"    Vital signs include determination of blood pressure, which may be elevated in SLE or a primary vasculitis, and temperature. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Fever'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Musculoskeletal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pGALS (Pediatric Gait Arms Legs Spine) examination is a simple screen for musculoskeletal abnormalities that can be performed in minutes (",
"    <a class=\"graphic graphic_figure graphicRef51467 \" href=\"UTD.htm?21/3/21562\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65259 \" href=\"UTD.htm?1/52/1865\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76678 \" href=\"UTD.htm?1/58/1961\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57725 \" href=\"UTD.htm?31/10/31912\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. It is a screen that uses simple physical maneuvers, including observation of the gait, to assess for musculoskeletal abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Focused joint examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an affected joint is extremely painful, its assessment should be reserved until the end to encourage cooperation with the rest of the evaluation.",
"   </p>",
"   <p>",
"    The joint examination begins with inspection and proceeds to palpation and estimation of active and passive range of motion (",
"    <a class=\"graphic graphic_table graphicRef55468 \" href=\"UTD.htm?31/56/32652\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1177603\">",
"    <span class=\"h3\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation is the first step in joint examination. If joint pain is asymmetrical, compare both extremities looking for differences in size and shape. Does the child hold an affected joint in a particular position of comfort? If a joint appears bigger than the corresponding contralateral articulation, further assessment will need to determine if joint effusion, synovial thickening, edema of the soft tissue overlying the joint, bony overgrowth, or some combination of these abnormalities has led to the increase in joint size. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Palpation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Even if only a single joint is painful, the entire extremity should be examined to detect the presence of muscle atrophy, discrepancies of length,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    generalized asymmetry. If there is a leg length discrepancy, measure the leg lengths carefully from the anterior superior iliac spine to the medial malleolus to distinguish an apparent difference due to a pelvic tilt from a true difference in length. Alternatively, a pelvic tilt in the standing position may be observed from behind, and correcting the tilt by placing a lift under (\"blocking up\") the shorter leg should give an accurate estimate of leg length discrepancy.",
"   </p>",
"   <p>",
"    The skin overlying the joint should be inspected for evidence of scars, bruises, and discoloration, which could be caused by a rash or inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in palpation is to detect any changes in the temperature of the skin overlying the affected joint. Increased warmth of the affected joint compared to the unaffected side could indicate inflammation due to infection or rheumatologic disorder. Extremities affected by complex regional pain syndrome (CRPS) Type 1 can be either cooler or warmer than the unaffected side.",
"   </p>",
"   <p>",
"    Palpation includes assessment for the presence and location of tenderness. Joint tenderness may be secondary to disorders of the bone, such as osteomyelitis, bone tumor, or Osgood-Schlatter disease; synovial disease, such as arthritis; or abnormalities of the ligaments, tendons, and menisci. Palpation of the \"entheses\" (points of insertion of ligament, tendon or joint capsule into bone) is of particular importance in determining the subtype of JIA and occasionally in other musculoskeletal and rheumatic diseases. Inflammation at these points of insertion is referred to as \"enthesitis\".",
"   </p>",
"   <p>",
"    If osteomyelitis is suspected, careful palpation of the bone should start away from the painful area and move towards it slowly. In a febrile child, severe pain in a localized area of bone (\"point tenderness\") is indicative of possible osteomyelitis. In a non-febrile child, there is a wide differential diagnosis for point bone tenderness, including fracture, periostitis, benign or malignant neoplasia, and enthesitis.",
"   </p>",
"   <p>",
"    If swelling is present, palpation may help determine the nature of the enlargement. A cystic or fluctuant quality to the swelling suggests a fluid collection that may be indicative of a joint effusion, ganglion, meniscal cyst, bursal swelling, or abscess. A doughy or rubbery consistency suggests synovial thickening, whereas, a hard, bony feel may indicate osseous overgrowth (eg, bone tumor or exostosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Range of motion (ROM) is an important part of the examination of a child with joint pain; however, if there is severe pain, particularly if there is a history of trauma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an obvious deformity, it is prudent to splint the involved joint and proceed to obtain radiographs to rule out a fracture or dislocation. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Diagnostic studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the absence of severe pain, deformity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of significant trauma, joint function is assessed with the following questions in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the ROM limited, and if so, to what degree? Keep in mind that while most joints are limited in movement to flexion and extension, a few joints move in other planes resulting in a greater ROM. These include the hips, shoulders, spine, wrists, and ankles. Active and passive range of motion should be noted in abduction and with internal and external rotation of the hips and shoulders.",
"      <br/>",
"      <br/>",
"      Of note, one of the biggest mistakes that nonspecialists make when testing passive ROM is not pushing the joint to the limits of its range of motion. Frequently in arthritis and other inflammatory conditions, there may be very subtle abnormalities that are missed when this is not done. As an example, in the knee, where loss of the normal few degrees of \"relaxed passive extension\" may be the only indication of knee pathology, a few degrees of motion may be the sole distinguishing feature between an arthritic joint and a normal one. To demonstrate this finding, while the child lies supine and relaxed with the legs extended, the feet are gently lifted off the bed by the examiner. If there is asymmetry of the expected 5 to 10 degrees hyperextension of the knees, pathology is generally found in the side that has \"lost\" relaxed passive extension.",
"     </li>",
"     <li>",
"      Is there excessive joint mobility [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/8\">",
"       8",
"      </a>",
"      ]? Excessive mobility of the joint, which may be associated with joint pain, can be seen in benign hypermobility syndrome and in pathologic joint laxity syndromes such as Ehlers Danlos or Marfan's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=see_link\">",
"       \"Clinical manifestations and treatment of the hypermobility syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is there pain with motion? If palpation and movement of the painful joint do not reproduce or exacerbate the pain, then referred pain should be suspected. As an example, knee pain may arise from a problem at the hip. If the hip and knee are normal on examination, consider an even more proximal site, such as the spine or retroperitoneum. For example, pyomyositis of the psoas (psoas abscess) typically presents with hip pain and flexion deformity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Is muscle strength normal? Muscle weakness, especially proximal weakness, may be an indication of myopathy, such as dermatomyositis or muscular dystrophy. The inflammatory myopathies in particular may be associated with joint symptoms as well as muscle pain and weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Specific joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are separate topics that review the pediatric evaluation of pain and injury of specific joints.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neck (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link\">",
"       \"Approach to the young athlete with neck pain or injury\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Foot and ankle (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14711?source=see_link\">",
"       \"Evaluation of foot and ankle pain in the young athlete\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Knee (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"       \"Approach to the young athlete with acute knee pain or injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"       \"Approach to the young athlete with chronic knee pain or injury\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hip (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of hip pain in childhood\", section on 'Specific causes'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic studies should be done judiciously and chosen on the basis of likely diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/9\">",
"     9",
"    </a>",
"    ]. In fact, most rheumatologic disorders affecting children are diagnosed based upon the history and physical examination. Diagnostic studies may help to exclude other conditions or support one's clinical impression, but rarely do they reveal a previously unsuspected diagnosis. A particular danger for the inexperienced clinician is finding and dealing with irrelevant or inconsequential \"abnormalities\" as a result of performing an overenthusiastic battery of investigations. The addition of selective imaging and laboratory testing to a complete and thorough history and physical examination may help to establish the cause of joint abnormalities. However, some of the most common rheumatic diseases of children, such as JIA, may have few or no associated laboratory abnormalities. If the cause remains elusive despite a comprehensive evaluation, or if a disease or disorder requiring a specialist's expertise is discovered or suspected, referral to a pediatric rheumatologist or orthopedist is often a more efficient approach than performing numerous imaging and laboratory studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Joint aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of septic arthritis should be considered carefully in a child with an acute monoarthritis, and if there is any suspicion or uncertainty, joint aspiration and examination of the synovial fluid should be performed to either make the diagnosis or rule it out.",
"   </p>",
"   <p>",
"    For most children with joint swelling and pain, however, even when only one joint is affected, joint aspiration is usually not necessary. Unlike the situation in adults, in whom other illnesses, such as gout, make arthrocentesis a more important diagnostic tool, joint aspirations rarely add useful information in children.",
"   </p>",
"   <p>",
"    If joint aspiration is required, older children usually can tolerate it with the use of local anesthetic. Younger children and those requiring aspiration of a shoulder or hip may require procedural sedation or general anesthesia. Hip joint aspiration should be performed with ultrasonographic guidance by someone skilled in this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=see_link\">",
"     \"Joint aspiration or injection in children: Indications, technique, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following testing is performed routinely on synovial fluid, although Gram stain and culture are undoubtedly the most useful:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cell count and differential &mdash; High white cell count is indicative of an inflammatory process, such as JIA or septic arthritis",
"     </li>",
"     <li>",
"      Gram stain",
"     </li>",
"     <li>",
"      Glucose",
"     </li>",
"     <li>",
"      Protein",
"     </li>",
"     <li>",
"      Microbiology (aerobic and anaerobic bacterial cultures)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of the joint fluid for crystals is rarely informative in children. Gouty arthritis is very rare before puberty, even in children with Lesch-Nyhan syndrome (hypoxanthine-guanine phosphoribosyltransferase deficiency) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain radiograph of the affected joint should be performed to rule out fractures, periostitis, avascular necrosis, bone tumors, and bone dysplasias. Simultaneous imaging of the contralateral joint allows for comparison of growth and development; unilateral acceleration may be a sign of chronic inflammation.",
"   </p>",
"   <p>",
"    In patients with hip involvement, ultrasonography is particularly useful in detecting joint effusion.",
"   </p>",
"   <p>",
"    Computerized axial tomography (CT) scans and magnetic resonance imaging (MRI) scans are generally reserved for evaluating noninflammatory conditions and should be discussed with the appropriate radiologist prior to ordering the study. MRI may be useful in differentiating infectious arthritis from recent-onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Technetium bone scans can be helpful in differentiating septic arthritis from osteomyelitis when the clinical examination does not separate the two [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/12\">",
"     12",
"    </a>",
"    ]. It is also used for detecting unsuspected skeletal trauma and tumors, such as osteoid osteoma. Perhaps the most common use of these scans is attempting to localize symptoms in a non-acute situation when the source or location of the patient's pain remains unclear after the clinical examination. In fact, imaging is seldom as useful as the examination of an experienced practitioner, since bone scans primarily detect abnormal tracer uptake by osteoblasts, a type of cell not affected by potential causes of joint symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Radiologic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=see_link\">",
"     \"Diagnostic imaging of joint pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory tests should be considered in any child with acute or chronic joint pain without an immediately obvious cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count and differential to detect abnormalities of blood cell lines that may be associated with SLE, systemic JIA, bacterial and viral infections, and leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute-phase reactants (erythrocyte sedimentation rate or C reactive protein). When elevated, these tests are nonspecific markers of inflammation. However, many children with inflammatory diseases, such as JIA, may have normal acute phase reactants values.",
"     </li>",
"     <li>",
"      Serum chemistries, especially liver and kidney function tests. (Abnormal values may be indicative of a possible systemic disorder, such as SLE or vasculitis).",
"     </li>",
"     <li>",
"      Serum lactate dehydrogenase (LDH) (elevated levels may be indicative of the presence of malignant neoplasm [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]) and creatine kinase (elevated levels may be indicative of myositis).",
"     </li>",
"     <li>",
"      Urinalysis to detect urinary abnormalities that may be associated with some rheumatologic disorders such as SLE and Henoch-Sch&ouml;nlein purpura (IgA vasculitis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evaluation is dependent upon whether the joint symptoms are acute or chronic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Acute joint pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute joint pain, either as a solitary manifestation or when accompanied by systemic symptoms, may be directly or indirectly related to an infectious process; therefore, the following tests may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cultures of the throat, blood, joint fluid, stool,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine",
"     </li>",
"     <li>",
"      Serologic testing for Lyme disease for children who live in or have visited an endemic area, since one of the most common late or chronic manifestations of Lyme disease is an acute pauciarthritis",
"     </li>",
"     <li>",
"      Antistreptolysin-O (ASO) titer or similar studies looking for evidence of a recent streptococcal infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Chronic joint pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic joint pain is unlikely to be related to an infectious process, the primary exceptions being the arthritis of Lyme disease or tuberculosis.",
"   </p>",
"   <p>",
"    The following tests should be considered in children with chronic as opposed to acute symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Quantitative immunoglobulins to detect immune deficiencies",
"     </li>",
"     <li>",
"      Serologic testing for Lyme disease",
"     </li>",
"     <li>",
"      Antinuclear antibody (ANA)",
"     </li>",
"     <li>",
"      Rheumatoid factor (RF)",
"     </li>",
"     <li>",
"      HLA-B27 (presence is associated with juvenile ankylosing spondylitis, psoriatic arthritis, arthritis associated with inflammatory bowel disease, and reactive arthritis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, many of these tests, especially ANA and RF, are generally not useful because they have a high false positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/17\">",
"     17",
"    </a>",
"    ] and are often negative in children with rheumatologic disorders, such as JIA. It is important to avoid the pitfall of eliminating rheumatologic conditions as a possible diagnosis based upon negative results of these tests, when the majority of children with JIA will have normal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    negative ANA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RF [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14057/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis for joint pain and swelling is broad, ranging from benign to serious conditions, some of which can have devastating consequences (",
"      <a class=\"graphic graphic_table graphicRef57734 \" href=\"UTD.htm?23/29/24029\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A complete history may differentiate between benign and pathologic conditions, especially those that require immediate medical attention, and helps direct the physical examination and work-up.",
"     </li>",
"     <li>",
"      The important elements of the history include characterization of the pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swelling (ie, site, severity, frequency and duration of symptoms, and the number of joints involved) (",
"      <a class=\"graphic graphic_table graphicRef78083 \" href=\"UTD.htm?42/12/43211\">",
"       table 2",
"      </a>",
"      ), presence of other joint findings (instability, warmth and redness) and precipitating factors (antecedent infection or trauma, and level of activity), review of other associated non-musculoskeletal symptoms (eg, fever and rash) (",
"      <a class=\"graphic graphic_table graphicRef56247 \" href=\"UTD.htm?25/22/25965\">",
"       table 3",
"      </a>",
"      ), and the presence of other medical conditions associated with arthritis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormalities detected by the physical examination may be important clues to the diagnosis and help differentiate severe conditions requiring urgent medical intervention from more benign disorders. A thorough physical examination includes general inspection including measurement of growth parameters and vital signs, screening of the entire musculoskeletal system (",
"      <a class=\"graphic graphic_figure graphicRef51467 \" href=\"UTD.htm?21/3/21562\">",
"       figure 1",
"      </a>",
"      ) as well as a focused examination of the affected joint(s) (",
"      <a class=\"graphic graphic_table graphicRef55468 \" href=\"UTD.htm?31/56/32652\">",
"       table 4",
"      </a>",
"      ), and evaluation of motor strength to detect any neuromuscular conditions that may be accompanied by joint symptoms. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selective imaging and laboratory testing are directed by the history and physical examination. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the cause of joint pain or swelling remains elusive despite a comprehensive evaluation, or if a disease or disorder requiring a specialist's expertise is discovered or suspected, referral to a pediatric rheumatologist or orthopedist may be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/1\">",
"      Foster H, Kimura Y. Ensuring that all paediatricians and rheumatologists recognise significant rheumatic diseases. Best Pract Res Clin Rheumatol 2009; 23:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/2\">",
"      Sherry DD, Bohnsack J, Salmonson K, et al. Painless juvenile rheumatoid arthritis. J Pediatr 1990; 116:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/3\">",
"      Fink CW, Nelson JD. Septic arthritis and osteomyelitis in children. Clin Rheum Dis 1986; 12:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/4\">",
"      Uziel Y, Hashkes PJ. Growing pains in children. Pediatr Rheumatol Online J 2007; 5:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/5\">",
"      Riise &Oslash;R, Handeland KS, Cvancarova M, et al. Incidence and characteristics of arthritis in Norwegian children: a population-based study. Pediatrics 2008; 121:e299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/6\">",
"      Foster HE, Kay LJ, Friswell M, et al. Musculoskeletal screening examination (pGALS) for school-age children based on the adult GALS screen. Arthritis Rheum 2006; 55:709.",
"     </a>",
"    </li>",
"    <li>",
"     www.arc.org.uk/arthinfo/medpubs/6535/6535.asp (Accessed on August 13, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/8\">",
"      Smits-Engelsman B, Klerks M, Kirby A. Beighton score: a valid measure for generalized hypermobility in children. J Pediatr 2011; 158:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/9\">",
"      Ansell BM. Rheumatic disease mimics in childhood. Curr Opin Rheumatol 2000; 12:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/10\">",
"      Treadwell BL. Juvenile gout. Ann Rheum Dis 1971; 30:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/11\">",
"      Kirkhus E, Flat&oslash; B, Riise O, et al. Differences in MRI findings between subgroups of recent-onset childhood arthritis. Pediatr Radiol 2011; 41:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/12\">",
"      ter Meulen DC, Majd M. Bone scintigraphy in the evaluation of children with obscure skeletal pain. Pediatrics 1987; 79:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/13\">",
"      Jones OY, Spencer CH, Bowyer SL, et al. A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis. Pediatrics 2006; 117:e840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/14\">",
"      Wallendal M, Stork L, Hollister JR. The discriminating value of serum lactate dehydrogenase levels in children with malignant neoplasms presenting as joint pain. Arch Pediatr Adolesc Med 1996; 150:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/15\">",
"      Malleson PN, Sailer M, Mackinnon MJ. Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 1997; 77:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/16\">",
"      Eichenfield AH, Athreya BH, Doughty RA, Cebul RD. Utility of rheumatoid factor in the diagnosis of juvenile rheumatoid arthritis. Pediatrics 1986; 78:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/17\">",
"      Cabral DA, Tucker LB. Malignancies in children who initially present with rheumatic complaints. J Pediatr 1999; 134:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14057/abstract/18\">",
"      McGhee JL, Burks FN, Sheckels JL, Jarvis JN. Identifying children with chronic arthritis based on chief complaints: absence of predictive value for musculoskeletal pain as an indicator of rheumatic disease in children. Pediatrics 2002; 110:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6405 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-A67B6C3D87-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14057=[""].join("\n");
var outline_f13_46_14057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pain, swelling, and stiffness characterization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Severity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Location and number of involved joints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Frequency, duration, and pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other joint symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Antecedent trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Antecedent infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Inactivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Increased physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Review of systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Musculoskeletal screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Focused joint examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1177603\">",
"      - Inspection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Specific joints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Joint aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Acute joint pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Chronic joint pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6405|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/3/21562\" title=\"figure 1\">",
"      Musculoskeletal screen 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/52/1865\" title=\"figure 2\">",
"      Musculoskeletal screen 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/58/1961\" title=\"figure 3\">",
"      Musculoskeletal screen 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/10/31912\" title=\"figure 4\">",
"      Musculoskeletal screen 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6405|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/29/24029\" title=\"table 1\">",
"      Diff dx joint pain child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/12/43211\" title=\"table 2\">",
"      History joint pain child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/22/25965\" title=\"table 3\">",
"      ROS joint pain swell child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/56/32652\" title=\"table 4\">",
"      Joint exam child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=related_link\">",
"      Approach to the child with a limp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=related_link\">",
"      Approach to the young athlete with acute knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=related_link\">",
"      Approach to the young athlete with chronic knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=related_link\">",
"      Approach to the young athlete with neck pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=related_link\">",
"      Clinical manifestations and treatment of the hypermobility syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=related_link\">",
"      Complex regional pain syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=related_link\">",
"      Diagnostic imaging of joint pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14711?source=related_link\">",
"      Evaluation of foot and ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=related_link\">",
"      Growing pains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=related_link\">",
"      Joint aspiration or injection in children: Indications, technique, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=related_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=related_link\">",
"      Overview of the causes of limp in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_46_14058="Small bowel obstruction: Causes and management";
var content_f13_46_14058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Small bowel obstruction: Causes and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14058/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14058/contributors\">",
"     Richard A Hodin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14058/contributors\">",
"     Liliana Bordeianou, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14058/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14058/contributors\">",
"     David I Soybel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14058/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/46/14058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/46/14058/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/46/14058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small bowel obstruction (SBO) occurs when the normal flow of intestinal contents is interrupted. Postoperative adhesions are the most common cause of mechanical SBO, which cause extrinsic compression of the intestine. Malignant tumors or strictures of the small bowel can cause intrinsic blockage and are the second leading cause of SBO. Hernias cause extrinsic compression and are the third most common cause of SBO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/1\">",
"     1",
"    </a>",
"    ]. Intussusception, volvulus, Crohn's disease, and gallstones (gallstone ileus) account for only a small percentage of cases (",
"    <a class=\"graphic graphic_table graphicRef53183 \" href=\"UTD.htm?12/3/12347\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will focus on the causes and treatment of SBO. The clinical manifestations and diagnosis of SBO are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF OBSTRUCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative adhesions cause the majority of small bowel obstructions. The risk of developing an obstruction after surgery from postoperative adhesions is estimated to be 9 percent within the first year after abdominal surgery, 19 percent by 4 years, and 35 percent by 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Population based studies have shown that 24 percent of patients undergo surgery for SBO during their index admission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/6\">",
"     6",
"    </a>",
"    ]. Of those who underwent surgery, 38 percent had lysis of adhesions, 18 percent had lysis of adhesions with a small bowel resection, and the remainder had a hernia repair or a small bowel resection with a hernia repair [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of SBO due to adhesions depends in part upon the type of surgery being performed and the cause of the SBO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/7\">",
"     7",
"    </a>",
"    ]. A study comparing open appendectomy to open cholecystectomy in a series of 567 patients showed that obstruction was significantly more common after appendectomy (10.7 versus 6.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of 446,331 abdominal operations, ileal pouch&ndash;anal anastomosis were associated with the highest incidence of SBO (19 percent), followed by open colectomy (9 percent). The incidence of adhesive SBO was higher in open operations than with laparoscopic surgery (eg, 7 percent in open cholecystectomies versus 0.2 percent in laparoscopic cholecystectomies). The decrease in the frequency of postoperative adhesions with laparoscopic surgery, despite the fact that the procedures and dissection are similar to those done with the open approach, has been documented in other studies as well [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/9\">",
"     9",
"    </a>",
"    ]. The cause for the differences in the rates of postoperative adhesions between open and laparoscopic surgery is not clear, but likely relates to the degree of manipulation and trauma to the intra-abdominal tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant tumors are the second most common cause of SBO, accounting for about 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/1\">",
"     1",
"    </a>",
"    ]. SBO has been described in as many as 42 percent of women with ovarian carcinoma and 28 percent of patients with colorectal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28070?source=see_link\">",
"     \"Surgery for recurrent epithelial ovarian cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19930?source=see_link\">",
"     \"Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hernias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hernias are the third leading cause of intestinal obstruction and account for approximately 10 percent of all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/1\">",
"     1",
"    </a>",
"    ]. Ventral and inguinal hernias are most commonly represented, although internal hernias, femoral, obturator and parastomal hernias also occur.",
"   </p>",
"   <p>",
"    Congenital and acquired internal hernias cause 0.6 to 5.8 percent of cases of SBO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/11\">",
"     11",
"    </a>",
"    ]. An obturator hernia occurs through the pelvic obturator canal, a rigid ring made up of the underside of the superior pubic ramus and the obturator fascia. It accounts for 0.2 to 0.4 percent of obstructions in the United States and is referred to as \"little old ladies' hernia\" because it is most common in emaciated older women. Obturator hernias have been associated with a mortality of 25 percent due to the difficulty in diagnosis and the population in which it occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other types of congenital internal hernias include paraduodenal, transmesenteric, and transomental hernias. Acquired internal hernias are often caused by failure to close mesenteric defects after bowel resection or by other artificially created foraminae through which small bowel can herniate. Diagnosis is rarely made preoperatively, as presentation is indistinguishable from other causes of mechanical small bowel obstruction. Computed tomography can be useful in suspected cases of obturator hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Operative therapy includes reduction of herniated small bowel with resection of non-viable segments. There is debate regarding closure of the obturator canal as the tissues are difficult to approximate and recurrence complicates only 0 to 10 percent of cases without canal closure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/13\">",
"     13",
"    </a>",
"    ]. Other internal hernia defects should be closed after reduction of herniated small bowel has been achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraluminal stricture can be caused by a number of disorders including Crohn's disease, certain drugs such as enteric-coated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    solutions and NSAIDs, radiation therapy, ischemia, and tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection is avoided to the extent possible in patients with Crohn's disease because of the likelihood of subsequent resection and short bowel syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"       \"Surgical management of ulcerative colitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation therapy for abdominal malignancy can also cause stricture, especially in previously operated patients where adhesions may fix loops of small intestine within the field of radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/16\">",
"       16",
"      </a>",
"      ]. Because irradiated bowel heals poorly, operative treatment usually requires bypass [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/17\">",
"       17",
"      </a>",
"      ] or resection, with at least one side of the anastomosis being performed with nonirradiated bowel [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link\">",
"       \"Gastrointestinal toxicity of radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stricture can also result from an episode of mesenteric ischemia. Because the ileocolic artery is the last branch of the superior mesenteric artery, the usual site of ischemic stricture in the small bowel is the distal ileum [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link\">",
"       \"Acute mesenteric ischemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Small intestinal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraluminal neoplasms such as carcinoid, small bowel carcinoma, and lymphoma can cause obstruction. Symptoms usually develop gradually and progressively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/8/21642?source=see_link\">",
"     \"Treatment of small bowel neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Early postoperative obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early postoperative bowel obstruction is defined as occurring within 30 days of the initial operation. The incidence is estimated to be 1 to 4 percent. The cause is almost always adhesions unless the index operation was laparoscopic. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Laparoscopic treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Early postoperative obstruction and adynamic ileus can be distinguished clinically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nearly all patients with early postoperative bowel obstruction have an initial period of return of bowel function and oral intake, which is then followed by nausea, vomiting, abdominal pain, and distention [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with adynamic ileus do not experience a postoperative period of return of bowel function.",
"     </li>",
"     <li>",
"      Early postoperative bowel obstruction and adynamic ileus can be differentiated radiologically (plain films or CT scan) since patients with obstruction have a predominance of small bowel gaseous distention and a paucity of air in the colon [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management has traditionally been conservative, ie, nonoperative, for the first 7 to 14 days after diagnosis, since about 90 percent will resolve spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/22\">",
"     22",
"    </a>",
"    ]. The soft, filmy adhesions that develop early after operation do not generally cause strangulation and usually undergo",
"    <span class=\"nowrap\">",
"     dissolution/reformation,",
"    </span>",
"    thereby relieving the obstruction. Patients with signs or symptoms of strangulation should be operated on expeditiously.",
"   </p>",
"   <p>",
"    In contrast, early postoperative obstruction after laparoscopy usually requires operative intervention. One study demonstrated that virtually all patients in their series with postlaparoscopic obstruction eventually needed reoperation. In all cases, the cause of obstruction was small bowel incarcerated in a peritoneal defect caused by trocar placement or peritoneal incision for herniorrhaphy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the most likely cause of SBO after laparoscopy depends upon the procedure that was performed. SBO in the setting of simple laparoscopic cholecystectomy is almost always caused by a trocar site problem requiring surgical intervention. On the other hand, in more complicated laparoscopic procedures, other causes of obstruction may be seen.",
"   </p>",
"   <p>",
"    For example, following a laparoscopic gastric bypass to treat morbid obesity, patients may develop an internal hernia (\"Petersen Hernia\") through the defect created in the mesocolon through which the Roux limb passes (",
"    <a class=\"graphic graphic_figure graphicRef71580 \" href=\"UTD.htm?13/9/13458\">",
"     figure 1",
"    </a>",
"    ). Frequently these hernias present with a closed loop small bowel obstruction and need surgery. They should be suspected when a gastric bypass patient presents with symptoms of SBO and a CT scan shows dilatation in both the pancreaticobiliary and alimentary limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic small bowel obstruction caused by intramural hematoma results in nausea, vomiting, and upper abdominal tenderness. The duodenum is the most frequently involved segment of the bowel because it is fixed in the retroperitoneum and easily compressed between the abdominal wall and the vertebral column. A common cause is injury from a seat belt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis can be established with an upper gastrointestinal series. Patients who do not present with peritonitis can be managed conservatively with nasogastric suction and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=see_link\">",
"     \"Nutrition support in critically ill patients: Parenteral nutrition\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If obstruction persists longer than 14 days, some authors recommend surgery since irreversible intestinal fibrosis may have occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/26\">",
"     26",
"    </a>",
"    ]. If initial laparotomy is performed, the usual treatment is incision and drainage of the hematoma. Resection is rarely required. However, late fibrosis of the affected segment can occur and cause reobstruction due to gradual narrowing of the intestinal lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intussusception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intussusception is an \"internal prolapse\" of the bowel, that leads to obstruction and compromise of mesenteric blood flow, with resultant inflammation and the potential for ischemia of the bowel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/27\">",
"     27",
"    </a>",
"    ]. This occurs when a mass or lead point in the bowel (intussusceptum) is pulled forward by normal peristalsis, with resultant invagination or telescoping of the bowel wall (intussuscipiens) (",
"    <a class=\"graphic graphic_picture graphicRef71734 \" href=\"UTD.htm?32/61/33744\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bowel intussusception is rare in adults, and accounts for 1 to 5 percent of bowel obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/27\">",
"     27",
"    </a>",
"    ]. Adult intussusception commonly involves a distinct pathologic lead point, which is malignant in over half of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/11,27,29\">",
"     11,27,29",
"    </a>",
"    ]. Pediatric intussusception is usually due to a benign etiology and can usually be managed with non-operative reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"     \"Intussusception in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intussusceptions can be classified by etiology (benign lesion [eg, polyps], malignant lesion, or idiopathic) or by location:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Entero-enteric: Confined to the small bowel",
"     </li>",
"     <li>",
"      Colo-colic: Involving the large bowel only",
"     </li>",
"     <li>",
"      Ileo-colic: Prolapse of the terminal ileum within the ascending colon",
"     </li>",
"     <li>",
"      Ileo-cecal: The ileo-cecal valve is the leading point of intussusception",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms are often chronic; intermittent abdominal pain is the most common presentation in adults. Other common symptoms are those associated with intermittent partial bowel obstruction and can include nausea, vomiting, melena, weight loss, fever, and constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain abdominal films show small bowel obstruction. The diagnosis is most often made with computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/28\">",
"     28",
"    </a>",
"    ]. A \"target sign\" may be seen on CT on perpendicular view, while the intussusception will appear as a sausage shaped mass when the CT beam is parallel to the longitudinal axis. The distended loop of bowel (intussuscipiens) has a thickened wall because it represents two layers of bowel. However, target signs are sometimes seen on CT scans of patients who do not have a clinical presentation indicative of bowel obstruction. In such cases, the finding is of little clinical significance and is probably related to normal peristalsis.",
"   </p>",
"   <p>",
"    Because of the high percentage of associated malignancy, radiologic decompression is not appropriate in the adult population and surgical resection using appropriate oncologic techniques is recommended in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/27\">",
"     27",
"    </a>",
"    ]. However, if a benign diagnosis has been established preoperatively or the patient is at risk for short bowel syndrome, a combined approach with limited intestinal resections and snare polypectomies is more appropriate.",
"   </p>",
"   <p>",
"    An increased incidence of intussusception has been reported in patients with acquired immune deficiency syndrome (AIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/12,13,28\">",
"     12,13,28",
"    </a>",
"    ]. This is due to the high incidence of infectious and neoplastic conditions of the bowel in AIDS patients, such as lymphoid hyperplasia, Kaposi's sarcoma, and non-Hodgkin's lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bezoars",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal bezoars can be caused by high fiber dietary habits, poor dentition with resultant inability to properly chew food, and medications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/30\">",
"     30",
"    </a>",
"    ]. The usual therapy for obstruction due to gastrointestinal bezoar is laparotomy with enterotomy and removal of the offending bezoar. Endoscopy or gastrotomy can be used to remove or mince gastric bezoars at the time of surgery for bowel obstruction. Enzymatic digestion has also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13142?source=see_link\">",
"     \"Gastric bezoars\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gallstone ileus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstones cause 1 to 2 percent of small bowel obstructions and usually affects older patients. \"Gallstone ileus\" results from erosion and fistulization between the biliary and intestinal tracts, with the most common form being cholecystoduodenal fistula. Other possible entry sites include stomach, jejunum, ileum, and colon. Gallstones can also fistulize to the duodenum from the distal common bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26598?source=see_link\">",
"     \"Gallstone ileus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic signs include aberrantly located gallstones, pneumobilia, and bowel obstruction. Only one-half of the patients with gallstone ileus in one series had the diagnosis made preoperatively. The most common site of obstruction is the terminal ileum, and obstructing gallstones are reported to be 2.5 cm or larger in most series. Mortality rates are reported from 12 to 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical treatment for gallstone ileus in patients with significant comorbidities consists of enterolithotomy alone (open or laparoscopic) during the acute episode. Cholecystectomy and fistula takedown should be performed after the patient has recovered from the acute episode [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A one-stage procedure for gallstone ileus should be reserved for young, fit and low risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26692614\">",
"    <span class=\"h2\">",
"     Superior mesenteric artery syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superior mesenteric artery syndrome is an unusual cause of proximal intestinal obstruction. The syndrome is characterized by compression of the third portion of the duodenum due to narrowing of the space between the superior mesenteric artery and aorta and is primarily attributed to loss of the intervening mesenteric fat pad. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37799?source=see_link\">",
"     \"Superior mesenteric artery syndrome\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goals in the initial management of patients with SBO are to determine:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The degree of volume depletion and metabolic derangement",
"     </li>",
"     <li>",
"      The severity, cause, extent and location of the obstruction",
"     </li>",
"     <li>",
"      Whether nonoperative management can be considered",
"     </li>",
"     <li>",
"      The need for and timing of operative intervention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adequate intravenous (IV) access should be obtained for fluid resuscitation. Suspected impending or ongoing strangulation, with ischemia of an isolated segment of small bowel, warrants operative intervention as soon as possible, whereas other situations may permit a period of safe observation prior to surgery. Even if strangulation is suspected and operative intervention is planned, it may be necessary to resuscitate the patient in an intensive care unit, which can help to prevent hypotension upon the induction of anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Foley catheter should be placed to monitor urine output, and crystalloid solution (usually Lactated Ringer's), should be given until the patient makes urine or is clinically euvolemic. If necessary, a central venous catheter or Swan-Ganz catheter can be inserted to aid in fluid management, particularly in patients with history of congestive heart failure.",
"   </p>",
"   <p>",
"    The phrase &ldquo;never let the sun rise or set on a small bowel obstruction\" has long been a cardinal rule of general surgeons. To prevent strangulation of the intestine and its attendant morbidity and mortality, it has been recommended that clinically obstructed patients should be observed for no longer than 12 to 24 hours, after which time, if no improvement is seen, the patient should be brought to surgery. Although this clinical \"pearl\" is still valid and&nbsp;clinicians should maintain a&nbsp;high index of suspicion for possible strangulation, the common use of&nbsp;computed tomography (CT) of the abdomen in patients with abdominal pain has led to an appropriate modification in clinical practice. In some patients, the findings on CT scan are suggestive of a complicated obstruction (eg, strangulation, perforation) and urgent exploration&nbsp;is indicated. On the other hand, if the CT scan shows an uncomplicated obstruction (eg, partial), one can be more secure in giving the patient a period of time that is longer than 24 hours to resolve the obstruction",
"   </p>",
"   <p>",
"    Prompt surgical intervention is warranted in patients with obstruction in which there is no prior history of abdominal surgery (so-called \"de novo\" obstruction) or cases in which closed-loop obstruction or strangulation are strongly suspected. Radiologic demonstration of mesenteric ischemia or closed-loop obstruction in any patient should also prompt surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NONOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonoperative management with nasogastric suction and IV fluids can sometimes be successful in patients with partial SBO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/1,6,35\">",
"     1,6,35",
"    </a>",
"    ]. This includes patients with partial SBO due to metastatic intraabdominal malignancy, recurrent adhesive obstruction, obstructing radiation enteritis, or during the early postoperative period.",
"   </p>",
"   <p>",
"    Antibiotics are not indicated in the routine nonoperative management of uncomplicated small bowel obstruction. Patients who develop complications of small bowel obstruction that indicate the need for surgery should receive prophylactic antibiotics perioperatively. &nbsp;(See",
"    <a class=\"local\" href=\"#H18\">",
"     'Operative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Safe nonoperative management of small bowel obstruction requires that small bowel strangulation be ruled out to the extent possible. Mortality for patients with gangrenous strangulated obstruction is substantially higher than for patients with simple mechanical obstruction relieved within 24 hours (4.5 to 31 versus approximately 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frequent clinical reassessments of the patient are required to ensure that there are no developing signs of strangulation. If there is concern that the patient has increasing pain, distension and persistent high NG output, surgical exploration should be considered.",
"   </p>",
"   <p>",
"    It is difficult to accurately predict strangulation preoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In one study, experienced clinicians were wrong more than one-half of the time for preoperative diagnoses of strangulation or no strangulation in patients eventually found to have gangrenous bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat CT scans may be helpful to detect early signs of bowel ischemia such as thickening of the small bowel wall",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mesentery, air in the bowel wall, or ascitic fluid. There is little role for repeated plain abdominal films, given that such x-rays can only detect the latest stage of obstruction (ie, perforation with free air).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nasogastric tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of nasogastric (NG) tubes in the setting of a small bowel obstruction remains a matter of clinical judgment and may differ from patient to patient. In patients with complete or high-grade small bowel obstruction, placement of a nasogastric tube can decompress the distended stomach and improve patient comfort.",
"   </p>",
"   <p>",
"    A soft 14 French, well lubricated NG tube works well and should be placed with the patient in the upright sitting position. An NG tube of this size has a better chance of sumping and suctioning intestinal contents efficiently than a smaller tube. It is helpful to provide the patient with a cup of water and a straw, and to take advantage of the patient's own swallowing mechanism to pass the tube into the esophagus and then into the stomach. Excessive gagging along with the inability to speak suggests that the tube may be within the trachea, and should therefore be withdrawn and replaced.",
"   </p>",
"   <p>",
"    Ideally, the tip of the tube should placed into the most dependent portion of the stomach. Instillation of air while listening over the epigastrium is not an accurate way to ensure that the tube is in proper position since the air may be heard even if the tip of tube is in too far or not far enough. Aspiration of gastric contents through the tube indicates that the tip lies within the gastrointestinal tract. As an alternative, the tube can be flushed with 20 to 30 cc of warm water and then an attempt made to suck the water back into the tube with a large syringe. If most of the instilled water can be retrieved, the tube is likely in the proper position. If the fluid cannot be drawn back, the tube should be readjusted and the test repeated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ideal tube positioning is documented with a plain x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/40\">",
"     40",
"    </a>",
"    ]. Once the NG tube is in its proper position, it should be taped to the nose securely, but care should be taken not to push the tube up against the nares too tightly with the tape as this can cause pressure necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/41\">",
"     41",
"    </a>",
"    ]. The NG tube should then be placed on intermittent low wall suction.",
"   </p>",
"   <p>",
"    Many patients experience discomfort related to the gag reflex, which will almost always pass within 24 to 48 hours. Several small randomized trials have shown that instillation of local anesthetic sprays (eg, preservative free",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    spray, 4 percent delivered by single dose atomizer to the nose and pharynx) into the oropharynx can help alleviate some of the gag reflex and discomfort associated with the placement of an NG tube [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of new chest pain suggestive of acid reflux in a patient with a newly placed nasogastric tube may indicate the development of esophagitis and the nasogastric tube should ideally be removed. For patients who still require an NG tube, suppression of gastric acid secretion to decrease the acidity of the material that refluxes into the esophagus is helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The amount of output from the NG tube should be carefully documented to help with clinical judgments regarding the progression or resolution of the obstruction, and the requirement for IV hydration. Nasogastric losses can be replaced with IV normal saline plus KCL (30 to 40",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resolution of a small bowel obstruction is generally accompanied by a decrease in abdominal distension, the passage of flatus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stool per rectum, and a decrease in the volume of nasogastric tube output. In cases where the obstruction is clearly resolved, the nasogastric tube can be simply removed and the diet advanced as tolerated. In cases where the resolution of the obstruction is not so clear, the tube can be clamped for periods of four hours at a time and residuals checked. If the residuals are less than 100 cc after four hours and the patient is not nauseated, the tube can usually be safely removed as this indicates that most of the gastric contents are emptying normally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Long decompression tubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of long decompression tubes (such as the Miller-Abbott tube) were used in the past in an attempt to decompress the bowel and avoid the need for surgery. The tubes were weighted with a mercury-filled balloon and passed into the stomach, after which the patient was placed into the right lateral decubitus position so that peristalsis would carry the tube beyond the pylorus and into the more distal jejunum. Older trials comparing standard nasogastric (NG) tubes and long tubes found no significant difference in the percentage of patients ultimately requiring surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/35,43\">",
"     35,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a later randomized trial comparing 90 patients managed with an endoscopically-placed long hydrophilic silicon tube with 96 patients managed with a NG tube found a significantly decreased time to relief of clinical SBO symptoms in the group managed with the long tube compared with the NG tube (4.1 versus 8.5 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/44\">",
"     44",
"    </a>",
"    ]. Overall effectiveness (ie, no need for surgery) was nearly doubled in the long tube group (90 versus 47 percent). The improved outcomes seen in this one study will need to be replicated in future studies; there remains concern over the potential risks of long tubes, such as knot formation, and thus, the effectiveness needs to be firmly established prior to its routine use. As such, we do not advocate the use of long tubes in patients with small bowel obstruction at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Water soluble contrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertonic water soluble contrast agents (eg, Gastrografin) can be used for both diagnostic and therapeutic purposes in the setting of partial small bowel obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/45\">",
"     45",
"    </a>",
"    ]. Gastrografin is a radio-opaque, water-soluble hypertonic liquid contrast agent given orally or through an NG tube.",
"   </p>",
"   <p>",
"    For diagnostic purposes, Gastrografin can be used in conjunction with a CT scan to reassess the bowel for signs of strangulation. The amount of Gastrografin to be administered generally ranges from 7.5 mL over 30 minutes to 22.5 mL over a course of 2 hours. This dose can be repeated if it is ineffective, with the caveat that use of more than a total of 100 mL of Gastrografin has not been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/46\">",
"     46",
"    </a>",
"    ]. Gastrografin draws fluid into the lumen due to its hypertonic constitution. The fluid shifts decrease intestinal wall edema and stimulate intestinal peristalsis, thereby improving bowel function and decreasing length of stay [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/46-50\">",
"     46-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of 14 prospective studies examining the diagnostic (seven studies) and therapeutic (eight trials) role of water soluble contrast agents (WCSA), the appearance of WSCA in the colon 4 to 24 hours after administration predicted resolution of the adhesive SBO with a sensitivity and specificity of 96 and 98 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the eight trials that examined the therapeutic role of WSCA, there was a significant reduction in the need for an operative intervention in patients randomly assigned to WSCA versus conventional therapy with bowel rest, nasogastric aspiration, and intravenous fluid rehydration (20.8 versus 29.6 percent, odds ratio 0.62, 95% CI 0.44-0.88). The WSCA group also had a significantly shorter hospital stay by almost two days.",
"   </p>",
"   <p>",
"    Abdominal radiographs should be performed no later than 24 hours after administration of the Gastrografin. In general, failure of the contrast to reach the colon 24 hours later should influence, but not dictate, the decision to operate. The time allowed for non-operative resolution following instillation of Gastrografin is a matter of clinical judgment in these patients. If there is concern that the patient has increasing pain, distension and persistent high NG output, surgical exploration should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of surgical intervention requires careful consideration. Approximately one-quarter of patients admitted for small bowel obstruction will require operation. Patients suspected on admission of having complicated obstruction with complete or closed-loop obstruction, patients with fever, leukocytosis, tachycardia, metabolic acidosis, continuous abdominal pain or peritonitis, or those who develop these signs and symptoms during the course of nonoperative management warrant prompt surgical exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/45\">",
"     45",
"    </a>",
"    ]. Although prophylactic antibiotics are not routinely administered for uncomplicated small bowel obstruction, antibiotics may be warranted for patients with complications (eg, perforation) (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Every patient considered for exploration due to a suspected small bowel obstruction, whether open or laparoscopically, should be appropriately resuscitated prior to surgery with IV fluids and have their electrolytes repleted, as indicated. This is especially important for patients with copious emesis resulting from more proximal obstruction, obstruction lasting several days, or obstruction causing large-volume intraluminal fluid sequestration. These patients may have severe metabolic acidosis, volume depletion, and electrolyte abnormalities, and need resuscitation prior to operation.",
"   </p>",
"   <p>",
"    The nature of the obstruction determines the type and extent of surgery. Incarcerated inguinal hernias causing obstruction can usually be treated through an inguinal incision even if bowel resection is required. Operative treatment of most other types of small bowel obstruction requires laparotomy or laparoscopy for exploration. However, the etiology of the obstruction cannot always be determined preoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Exploratory laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incision planning is critically important when performing exploratory laparotomy for small bowel obstruction. A new incision or extension of the previous incision in a cephalad direction will allow entry into a \"virgin\" area, avoiding adhesions and bowel loops adherent to the abdominal wall at the site of prior incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of the operation are to diagnose and resolve the source of the obstruction, resect any nonviable bowel and minimize the occurrence of an incidental enterotomy. An enterotomy or perforation will lead to peritoneal contamination with stagnant bowel contents with bacterial overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upon entering the peritoneal cavity, it is important to handle dilated bowel proximal to the point of obstruction gently because the bowel wall can be thin and is easily injured. Cultures of any cloudy fluid should be obtained. Ideally, the distal, decompressed bowel loops are identified first and followed to the point of obstruction. Dissection should start from the areas that are relatively free of scar to facilitate proper identification of anatomical structures along the way, thereby minimizing the chances of injury.",
"   </p>",
"   <p>",
"    Adhesiolysis is best done with appropriate and gentle traction to maximally expose the adhesion and then cutting the adhesion with sharp scissors or cautery. The adhesions can be gently stretched over the surgeon's index finger, allowing clear visibility and traction for division of adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/55\">",
"     55",
"    </a>",
"    ]. In rare cases, the density of the adhesions and close adherence of bowel loops may require a scalpel for effective adhesiolysis to be accomplished.",
"   </p>",
"   <p>",
"    The precise mechanism for the obstruction should be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/56\">",
"     56",
"    </a>",
"    ]. If there is one single adhesive band causing the obstruction, severing this band may be all that is necessary. If multiple broad based adhesions are present and multiple bowel loops are involved, an extensive lysis of adhesions may be required. Any internal hernias will require reduction of the herniated intestine and obliteration of the opening that allowed herniation.",
"   </p>",
"   <p>",
"    After the site of obstruction is relieved, the need for lysis of all remaining adhesions is debatable. It is probably best to lyse all adhesions, except in cases where the dissection is difficult and there is added concern about the possibility of an enterotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intraoperative assessment of viability",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the obstruction relieved, a critical part of the surgical approach to SBO is to assess bowel viability and decide whether any bowel needs to be resected. Assessment may be particularly challenging when relief of the bowel obstruction is achieved without bowel resection (such as in the presence of a hernia, adhesions, volvulus, and occasionally intussusception) and in the setting of a complete or closed-loop obstruction. The usual approach to assess bowel viability involves wrapping any questionably viable bowel in warm saline-soaked laparotomy pads and waiting 15 minutes prior to final assessment. Return of normal color, motility, and the presence of mesenteric pulses are signs used by most surgeons to indicate viable intestine.",
"   </p>",
"   <p>",
"    The use of subjective criteria to assess bowel viability may result in unnecessary resection of viable intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. An alternative technique involves the IV injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    (1000 mg) with subsequent illumination of the intestine using fluorescent light. Patchy fluorescence or areas of nonfluorescence indicate nonviable bowel. This technique has been found to be superior to standard clinical judgment and standard Doppler ultrasound examination in the setting of intestinal ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard Doppler examination may be useful in delineating the limits of resection of ischemic intestine in that pathologic evidence of progressive intestinal necrosis is found between 2 and 3 cm distal to the closest audible Doppler signal in dogs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/59\">",
"     59",
"    </a>",
"    ]. Laser Doppler flowmetry (LDF) is a refinement of the Doppler technique, which has also been found to be superior to clinical judgment in a prospective trial involving 48 segments of intestine in 13 patients with superior mesenteric arterial occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/60\">",
"     60",
"    </a>",
"    ]. Unfortunately LDF requires equipment that is not widely available.",
"   </p>",
"   <p>",
"    A number of other methods have been described, including pH studies, tonometry, surface oximetry, and myoelectric analysis. A practical approach is to evaluate questionably viable segments first clinically, then with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    if necessary. Standard Doppler examination (or LDF if available) can be used as an adjunctive technique in areas in which the fluorescein examination is difficult to interpret. Because marginally viable segments may survive in the short term only to become strictured later, it is probably better to err on the side of removing most questionable areas. However, in situations where removal of the entire length of marginally viable bowel can lead to short gut syndrome (eg. adhesions in a patient with prior resections for Crohn's disease), preserving bowel of borderline appearance is prudent. When bowel of borderline appearance is not resected, a reexploration 24 hours later is mandated to ascertain return of viability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laparoscopic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for laparoscopy continue to expand as surgeons become more comfortable with laparoscopic techniques and procedures. Several retrospective series of patients treated laparoscopically for small bowel obstruction have now been published [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. Patients without intraabdominal malignancy, inflammatory bowel disease, or more than one previous laparotomy for bowel obstruction are candidates for consideration of the laparoscopic approach. The best candidates for consideration of laparoscopic management include those with mild abdominal distention, proximal obstruction, partial obstruction and anticipated single band obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/45\">",
"     45",
"    </a>",
"    ]. Successful laparoscopic lysis of adhesions requires skilled surgeons and careful selection of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Success rates are in the range of 60 to 80 percent, and complications are rare but include iatrogenic perforation of the distended bowel. Most authors recommend that the initial trocar be placed via the open technique in an area of the abdomen not previously incised. The left upper quadrant is a suitable substitute location if the midline is not available. Subsequent trocars are placed under direct vision, and some authors recommend that the infraumbilical region be cleared of adhesions and a port placed there for camera insertion. Care is taken to use atraumatic grasping instruments to run the bowel so as to avoid perforation. An electric table will allow the patient to be tilted aggressively to the side and placed into the Trendelenburg and reverse Trendelenburg positions; this will allow the distended bowel to fall away from the area being examined. Most authors recommend beginning at the cecum with the patient in Trendelenburg position and tilted 30 degrees to the left, exposing the right lower quadrant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous retrospective reports indicate that laparoscopic treatment of small bowel obstruction is safe and effective. However, great care must be taken in lysing adhesions and manipulation of distended, edematous bowel. At least one trial indicates that this approach may result in earlier return of bowel function and shorter hospital stays than open surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/63\">",
"     63",
"    </a>",
"    ]. A randomized trial is needed to demonstrate that this procedure is cost-effective and beneficial to patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT OF SBO IN PATIENTS WITH MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some surgeons are reluctant to operate on patients with previous surgery for intraabdominal malignancy because they believe that an obstruction due to metastatic cancer is not likely to be relieved by surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the success of surgery for relieving obstruction in patients with cancer is reported as high as 71 percent in a series of 14 patients with malignant gastrointestinal obstruction due to recurrent ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/66\">",
"     66",
"    </a>",
"    ]. It should also be kept in mind that nonoperative therapy for malignant obstruction is also associated with high mortality (35 to 56 percent) and a high failure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H29#H29\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Bowel resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to differentiate malignant obstruction from obstruction due to other causes in patients with known malignancy. Even in obstructed patients with known recurrence, about one-third of obstructions are due to benign adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/68,70\">",
"     68,70",
"    </a>",
"    ]. In patients operated on for treatment of intraabdominal malignancy, obstructions due to recurrent cancer tend to occur earlier after surgery than adhesive obstructions (21 versus 61 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/67\">",
"     67",
"    </a>",
"    ]. Several recommendations for the care of these patients can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As with any patient with partial small bowel obstruction, a trial of nonoperative therapy is warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early surgery should be pursued in those without known recurrent cancer and with long intervals from diagnosis of malignancy to development of obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In those with partial obstruction and either recurrent malignancy or short interval to development of obstruction after surgery for malignancy, prolonged medical management may be offered [",
"      <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/69\">",
"       69",
"      </a>",
"      ]. Computed tomography (CT) or Positron Emission Tomography (PET) scans may be of help in distinguishing the cause of obstruction in those with a history of cancer without a known recurrence. In addition, the scans can provide evidence of overall disease burden, such that the long-term prognosis can be better assessed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in whom malignant obstruction cannot be relieved medically or surgically may require prolonged hospitalization and nasogastric tube drainage as well as administration of fluids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN). Alternatives include home TPN or gastrostomy tube placement with home electrolyte solution [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small studies have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , a somatostatin analog, can alleviate vomiting and even permit nasogastric tube removal in patients with terminal cancer and malignant bowel obstruction when traditional anti-nausea agents failed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Patients with end-stage malignancy may be best treated with comfort measures only. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts at prevention of small bowel obstruction have been focused largely on the prevention or control of adhesion formation. The earliest methods were mechanical and involved suturing or plicating the bowel during surgery for adhesive obstruction into patterns or conformations that would prevent subsequent obstruction. These methods have been found to be ineffective and fraught with complications, and are not currently used.",
"   </p>",
"   <p>",
"    Another mechanical means of preventing re-obstruction involves placement of a long intestinal tube, or Baker tube, via a jejunostomy. The Baker tube traverses the entire small bowel and the end of the tube is left in the distal ascending colon. This technique, known as \"sutureless plication,\" is intended to prevent postoperative kinking of the bowel during the 14 days it is left in place. The Baker tube is not frequently used and has not been definitively shown to decrease the incidence of recurrent adhesive bowel obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many different agents have been tried as chemical means of preventing postoperative adhesions. Application of high-molecular-weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    solution to peritoneal or denuded surfaces decreases adhesion formation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/79\">",
"     79",
"    </a>",
"    ]. However, along with this decrease comes an inhibition of the host's ability to wall off infection, as evidenced by an increased rate of peritonitis in experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One technology for adhesion prevention involves bioresorbable barrier membranes. Currently, there are two commercially available membranes. Both the \"Intercede\" membrane (oxygenated regenerated cellulose, Ethicon Inc, Somerville, New Jersey) and \"Seprafilm\" (sodium hyaluronate-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    , Genzyme Corp, Cambridge, Massachusetts), appear to be safe and effective in preventing adhesions to surfaces on which they are placed intraoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/80-84\">",
"     80-84",
"    </a>",
"    ]. These products are somewhat difficult to handle surgically and do not affect adhesion formation in other places in the abdomen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"     \"Preventing postoperative peritoneal adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective multicenter trial, Seprafilm did not decrease the incidence of postoperative small bowel obstruction, although SBO specifically due to adhesions were slightly decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/85\">",
"     85",
"    </a>",
"    ]. In a later controlled trial of 150 patients undergoing surgery for gastric cancer, there was no significant difference in the incidence of small bowel obstruction after three years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon some work in experimental animals, there has been concern that these agents will lead to an increase in the incidence of septic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/87,88\">",
"     87,88",
"    </a>",
"    ], but this was not seen in the two trials cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. These barriers should not be used to wrap intestinal anastomoses, since they can result in a higher leak rate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/46/14058/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lastly, laparoscopic surgery, when possible, appears to lead to a decrease in the frequency of postoperative adhesions. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Adhesions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/39/6770?source=see_link\">",
"       \"Patient information: Small bowel obstruction (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/22/42337?source=see_link\">",
"       \"Patient information: Ileus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small bowel obstruction (SBO) occurs when the normal flow of intestinal contents is interrupted. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequent causes of small bowel obstruction are postoperative adhesions, malignancies and hernias, which cause extrinsic compression of the intestine. Less frequently, strictures of the small bowel can cause intrinsic blockage. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes of obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management of patients with SBO includes volume resuscitation, correction of metabolic abnormalities and an assessment of the need for operative intervention. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonoperative management with nasogastric suction and intravenous fluids can sometimes be successful in patients with partial SBO. This approach requires frequent reassessments of the patient to ensure that there are no developing signs of strangulation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest giving a hypertonic water soluble contrast agent (eg, Gastrografin) as part of nonoperative treatment of partial small bowel obstruction (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients who receive Gastrografin have more rapid resolution of symptoms, a shorter length of hospital stay, and possibly less need for surgical intervention. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a period of observation prior to surgery for patients with partial small bowel obstruction, provided that small bowel strangulation has been ruled out to the extent possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients suspected of complete small bowel obstruction, suspicion for a strangulating mechanism should be greater, such that a lower threshold for surgical exploration should be adopted.",
"     </li>",
"     <li>",
"      Patients with suspected, impending, or ongoing strangulation require prompt operative intervention. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Operative management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/1\">",
"      Kendrick ML. Partial small bowel obstruction: clinical issues and recent technical advances. Abdom Imaging 2009; 34:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/2\">",
"      Parker MC, Ellis H, Moran BJ, et al. Postoperative adhesions: ten-year follow-up of 12,584 patients undergoing lower abdominal surgery. Dis Colon Rectum 2001; 44:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/3\">",
"      Rajab TK, Ahmad UN, Kelly E. Implications of late complications from adhesions for preoperative informed consent. J R Soc Med 2010; 103:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/4\">",
"      Ellis H, Moran BJ, Thompson JN, et al. Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study. Lancet 1999; 353:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/5\">",
"      Parker MC, Wilson MS, Menzies D, et al. Colorectal surgery: the risk and burden of adhesion-related complications. Colorectal Dis 2004; 6:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/6\">",
"      Foster NM, McGory ML, Zingmond DS, Ko CY. Small bowel obstruction: a population-based appraisal. J Am Coll Surg 2006; 203:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/7\">",
"      Barmparas G, Branco BC, Schn&uuml;riger B, et al. The incidence and risk factors of post-laparotomy adhesive small bowel obstruction. J Gastrointest Surg 2010; 14:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/8\">",
"      Zbar RI, Crede WB, McKhann CF, Jekel JF. The postoperative incidence of small bowel obstruction following standard, open appendectomy and cholecystectomy: a six-year retrospective cohort study at Yale-New Haven Hospital. Conn Med 1993; 57:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/9\">",
"      Indar AA, Efron JE, Young-Fadok TM. Laparoscopic ileal pouch-anal anastomosis reduces abdominal and pelvic adhesions. Surg Endosc 2009; 23:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/10\">",
"      Ripamonti C, De Conno F, Ventafridda V, et al. Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol 1993; 4:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/11\">",
"      Newsom BD, Kukora JS. Congenital and acquired internal hernias: unusual causes of small bowel obstruction. Am J Surg 1986; 152:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/12\">",
"      Bergstein JM, Condon RE. Obturator hernia: current diagnosis and treatment. Surgery 1996; 119:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/13\">",
"      Lo CY, Lorentz TG, Lau PW. Obturator hernia presenting as small bowel obstruction. Am J Surg 1994; 167:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/14\">",
"      ABBRUZZESE AA, GOODING CA. REVERSIBLE SMALL-BOWEL OBSTRUCTION: WITHDRAWAL OF HYDROCHLOROTHIAZIDE-POTASSIUM CHLORIDE THERAPY. JAMA 1965; 192:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/15\">",
"      Speed CA, Bramble MG, Corbett WA, Haslock I. Non-steroidal anti-inflammatory induced diaphragm disease of the small intestine: complexities of diagnosis and management. Br J Rheumatol 1994; 33:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/16\">",
"      Jackson BT. Bowel damage from radiation. Proc R Soc Med 1976; 69:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/17\">",
"      Mann WJ. Surgical management of radiation enteropathy. Surg Clin North Am 1991; 71:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/18\">",
"      Galland RB, Spencer J. Surgical management of radiation enteritis. Surgery 1986; 99:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/19\">",
"      Thaker P, Weingarten L, Friedman IH. Stenosis of the small intestine due to nonocclusive ischemic disease. Arch Surg 1977; 112:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/20\">",
"      Stewart RM, Page CP, Brender J, et al. The incidence and risk of early postoperative small bowel obstruction. A cohort study. Am J Surg 1987; 154:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/21\">",
"      Frager D, Medwid SW, Baer JW, et al. CT of small-bowel obstruction: value in establishing the diagnosis and determining the degree and cause. AJR Am J Roentgenol 1994; 162:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/22\">",
"      Pickleman J, Lee RM. The management of patients with suspected early postoperative small bowel obstruction. Ann Surg 1989; 210:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/23\">",
"      Velasco JM, Vallina VL, Bonomo SR, Hieken TJ. Postlaparoscopic small bowel obstruction. Rethinking its management. Surg Endosc 1998; 12:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/24\">",
"      Rogula T, Yenumula PR, Schauer PR. A complication of Roux-en-Y gastric bypass: intestinal obstruction. Surg Endosc 2007; 21:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/25\">",
"      Touloukian RJ. Protocol for the nonoperative treatment of obstructing intramural duodenal hematoma during childhood. Am J Surg 1983; 145:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/26\">",
"      Czyrko C, Weltz CR, Markowitz RI, O'Neill JA. Blunt abdominal trauma resulting in intestinal obstruction: when to operate? J Trauma 1990; 30:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/27\">",
"      Marinis A, Yiallourou A, Samanides L, et al. Intussusception of the bowel in adults: a review. World J Gastroenterol 2009; 15:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/28\">",
"      Gayer G, Zissin R, Apter S, et al. Pictorial review: adult intussusception--a CT diagnosis. Br J Radiol 2002; 75:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/29\">",
"      Nagorney DM, Sarr MG, McIlrath DC. Surgical management of intussusception in the adult. Ann Surg 1981; 193:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/30\">",
"      Robles R, Parrilla P, Escamilla C, et al. Gastrointestinal bezoars. Br J Surg 1994; 81:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/31\">",
"      Stitt RB, Heslin DJ, Currie DJ. Gall-stone ileus. Br J Surg 1967; 54:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/32\">",
"      Clavien PA, Richon J, Burgan S, Rohner A. Gallstone ileus. Br J Surg 1990; 77:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/33\">",
"      Moberg AC, Montgomery A. Laparoscopically assisted or open enterolithotomy for gallstone ileus. Br J Surg 2007; 94:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/34\">",
"      Muthukumarasamy G, Venkata SP, Shaikh IA, et al. Gallstone ileus: surgical strategies and clinical outcome. J Dig Dis 2008; 9:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/35\">",
"      Brolin RE, Krasna MJ, Mast BA. Use of tubes and radiographs in the management of small bowel obstruction. Ann Surg 1987; 206:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/36\">",
"      Stewardson RH, Bombeck CT, Nyhus LM. Critical operative management of small bowel obstruction. Ann Surg 1978; 187:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/37\">",
"      SILEN W, HEIN MF, GOLDMAN L. Strangulation obstruction of the small intestine. Arch Surg 1962; 85:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/38\">",
"      Sarr MG, Bulkley GB, Zuidema GD. Preoperative recognition of intestinal strangulation obstruction. Prospective evaluation of diagnostic capability. Am J Surg 1983; 145:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/39\">",
"      Ellett ML. What is known about methods of correctly placing gastric tubes in adults and children. Gastroenterol Nurs 2004; 27:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/40\">",
"      Baskin WN. Acute complications associated with bedside placement of feeding tubes. Nutr Clin Pract 2006; 21:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/41\">",
"      Banerjee TS, Schneider HJ. Recommended method of attachment of nasogastric tubes. Ann R Coll Surg Engl 2007; 89:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/42\">",
"      Gallagher EJ. Nasogastric tubes: hard to swallow. Ann Emerg Med 2004; 44:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/43\">",
"      Fleshner PR, Siegman MG, Slater GI, et al. A prospective, randomized trial of short versus long tubes in adhesive small-bowel obstruction. Am J Surg 1995; 170:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/44\">",
"      Chen XL, Ji F, Lin Q, et al. A prospective randomized trial of transnasal ileus tube vs nasogastric tube for adhesive small bowel obstruction. World J Gastroenterol 2012; 18:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/45\">",
"      Diaz JJ Jr, Bokhari F, Mowery NT, et al. Guidelines for management of small bowel obstruction. J Trauma 2008; 64:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/46\">",
"      Abbas SM, Bissett IP, Parry BR. Meta-analysis of oral water-soluble contrast agent in the management of adhesive small bowel obstruction. Br J Surg 2007; 94:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/47\">",
"      Di Saverio S, Catena F, Ansaloni L, et al. Water-soluble contrast medium (gastrografin) value in adhesive small intestine obstruction (ASIO): a prospective, randomized, controlled, clinical trial. World J Surg 2008; 32:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/48\">",
"      Kumar P, Kaman L, Singh G, Singh R. Therapeutic role of oral water soluble iodinated contrast agent in postoperative small bowel obstruction. Singapore Med J 2009; 50:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/49\">",
"      Assalia A, Schein M, Kopelman D, et al. Therapeutic effect of oral Gastrografin in adhesive, partial small-bowel obstruction: a prospective randomized trial. Surgery 1994; 115:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/50\">",
"      Biondo S, Par&eacute;s D, Mora L, et al. Randomized clinical study of Gastrografin administration in patients with adhesive small bowel obstruction. Br J Surg 2003; 90:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/51\">",
"      Branco BC, Barmparas G, Schn&uuml;riger B, et al. Systematic review and meta-analysis of the diagnostic and therapeutic role of water-soluble contrast agent in adhesive small bowel obstruction. Br J Surg 2010; 97:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/52\">",
"      Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/53\">",
"      Khan S, Gupta DK, Khan DN. Comparative study of three antimicrobial drugs protocol (Ceftriaxone, Gentamicin/Amikacin and Metronidazole) versus two antimicrobial drugs protocol (Ceftriaxone and Metronidazole) in cases of intra-abdominal sepsis. Kathmandu Univ Med J (KUMJ) 2005; 3:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/54\">",
"      Gonzenbach HR, Simmen HP, Amgwerd R. Imipenem (N-F-thienamycin) versus netilmicin plus clindamycin. A controlled and randomized comparison in intra-abdominal infections. Ann Surg 1987; 205:271.",
"     </a>",
"    </li>",
"    <li>",
"     Scott-Conner, CEH. Enterolysis for intestinal obstruction. In: Chassin's Operative Strategy in General Surgery, 3rd ed, Scott-Conner, CEH (Ed), Springer, New York 2002. p. 337.",
"    </li>",
"    <li>",
"     Pickleman, JR, Fischer, JE. Small and large bowel obstruction. In: Mastery of Surgery, 5th ed, Fischer, JE, Bland, KI (Eds), Lippincott, Philadelphia 2007. p. 1380.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/57\">",
"      Bulkley GB, Zuidema GD, Hamilton SR, et al. Intraoperative determination of small intestinal viability following ischemic injury: a prospective, controlled trial of two adjuvant methods (Doppler and fluorescein) compared with standard clinical judgment. Ann Surg 1981; 193:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/58\">",
"      Horgan PG, Gorey TF. Operative assessment of intestinal viability. Surg Clin North Am 1992; 72:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/59\">",
"      Cooperman M, Pace WG, Martin EW Jr, et al. Determination of viability of ischemic intestine by Doppler ultrasound. Surgery 1978; 83:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/60\">",
"      Redaelli CA, Schilling MK, B&uuml;chler MW. Intraoperative laser Doppler flowmetry: a predictor of ischemic injury in acute mesenteric infarction. Dig Surg 1998; 15:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/61\">",
"      Ibrahim IM, Wolodiger F, Sussman B, et al. Laparoscopic management of acute small-bowel obstruction. Surg Endosc 1996; 10:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/62\">",
"      Franklin ME Jr, Dorman JP, Pharand D. Laparoscopic surgery in acute small bowel obstruction. Surg Laparosc Endosc 1994; 4:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/63\">",
"      Strickland P, Lourie DJ, Suddleson EA, et al. Is laparoscopy safe and effective for treatment of acute small-bowel obstruction? Surg Endosc 1999; 13:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/64\">",
"      Mancini GJ, Petroski GF, Lin WC, et al. Nationwide impact of laparoscopic lysis of adhesions in the management of intestinal obstruction in the US. J Am Coll Surg 2008; 207:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/65\">",
"      Farinella E, Cirocchi R, La Mura F, et al. Feasibility of laparoscopy for small bowel obstruction. World J Emerg Surg 2009; 4:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/66\">",
"      Chi DS, Pha&euml;ton R, Miner TJ, et al. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist 2009; 14:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/67\">",
"      Richards WO, Williams LF Jr. Obstruction of the large and small intestine. Surg Clin North Am 1988; 68:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/68\">",
"      Butler JA, Cameron BL, Morrow M, et al. Small bowel obstruction in patients with a prior history of cancer. Am J Surg 1991; 162:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/69\">",
"      Gallick HL, Weaver DW, Sachs RJ, Bouwman DL. Intestinal obstruction in cancer patients. An assessment of risk factors and outcome. Am Surg 1986; 52:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/70\">",
"      Tang E, Davis J, Silberman H. Bowel obstruction in cancer patients. Arch Surg 1995; 130:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/71\">",
"      Ellis CN, Boggs HW Jr, Slagle GW, Cole PA. Small bowel obstruction after colon resection for benign and malignant diseases. Dis Colon Rectum 1991; 34:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/72\">",
"      Gemlo B, Rayner AA, Lewis B, et al. Home support of patients with end-stage malignant bowel obstruction using hydration and venting gastrostomy. Am J Surg 1986; 152:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/73\">",
"      August DA, Thorn D, Fisher RL, Welchek CM. Home parenteral nutrition for patients with inoperable malignant bowel obstruction. JPEN J Parenter Enteral Nutr 1991; 15:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/74\">",
"      Matulonis UA, Seiden MV, Roche M, et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage 2005; 30:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/75\">",
"      Khoo D, Hall E, Motson R, et al. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994; 30A:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/76\">",
"      Ripamonti C, Mercadante S, Groff L, et al. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 2000; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/77\">",
"      Weigelt JA, Snyder WH 3rd, Norman JL. Complications and results of 160 Baker tube plications. Am J Surg 1980; 140:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/78\">",
"      Rodriguez-Ruesga R, Meagher AP, Wolff BG. Twelve-year experience with the long intestinal tube. World J Surg 1995; 19:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/79\">",
"      Fabri PJ, Ellison EC, Anderson ED, Kudsk KA. High molecular weight dextran--effect on adhesion formation and peritonitis in rats. Surgery 1983; 94:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/80\">",
"      Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg 1996; 183:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/81\">",
"      Wiseman DM, Trout JR, Franklin RR, Diamond MP. Metaanalysis of the safety and efficacy of an adhesion barrier (Interceed TC7) in laparotomy. J Reprod Med 1999; 44:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/82\">",
"      Vrijland WW, Tseng LN, Eijkman HJ, et al. Fewer intraperitoneal adhesions with use of hyaluronic acid-carboxymethylcellulose membrane: a randomized clinical trial. Ann Surg 2002; 235:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/83\">",
"      Beck DE, Cohen Z, Fleshman JW, et al. A prospective, randomized, multicenter, controlled study of the safety of Seprafilm adhesion barrier in abdominopelvic surgery of the intestine. Dis Colon Rectum 2003; 46:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/84\">",
"      Kudo FA, Nishibe T, Miyazaki K, et al. Use of bioresorbable membrane to prevent postoperative small bowel obstruction in transabdominal aortic aneurysm surgery. Surg Today 2004; 34:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/85\">",
"      Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small-bowel obstruction by Seprafilm adhesion barrier after intestinal resection. Dis Colon Rectum 2006; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/86\">",
"      Hayashi S, Takayama T, Masuda H, et al. Bioresorbable membrane to reduce postoperative small bowel obstruction in patients with gastric cancer: a randomized clinical trial. Ann Surg 2008; 247:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/87\">",
"      Moreira H Jr, Wexner SD, Yamaguchi T, et al. Use of bioresorbable membrane (sodium hyaluronate + carboxymethylcellulose) after controlled bowel injuries in a rabbit model. Dis Colon Rectum 2000; 43:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/46/14058/abstract/88\">",
"      Tzianabos AO, Cisneros RL, Gershkovich J, et al. Effect of surgical adhesion reduction devices on the propagation of experimental intra-abdominal infection. Arch Surg 1999; 134:1254.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8038 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14058=[""].join("\n");
var outline_f13_46_14058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adhesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hernias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Small intestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Early postoperative obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intussusception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bezoars",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gallstone ileus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26692614\">",
"      Superior mesenteric artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NONOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nasogastric tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Long decompression tubes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Water soluble contrast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Exploratory laparotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intraoperative assessment of viability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laparoscopic treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT OF SBO IN PATIENTS WITH MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8038|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/9/13458\" title=\"figure 1\">",
"      Internal hernia defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8038|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/61/33744\" title=\"picture 1\">",
"      Ileocolonic intussusception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8038|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/3/12347\" title=\"table 1\">",
"      Causes of small bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 2\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26598?source=related_link\">",
"      Gallstone ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13142?source=related_link\">",
"      Gastric bezoars",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19930?source=related_link\">",
"      Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=related_link\">",
"      Nutrition support in critically ill patients: Parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/22/42337?source=related_link\">",
"      Patient information: Ileus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/39/6770?source=related_link\">",
"      Patient information: Small bowel obstruction (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=related_link\">",
"      Preventing postoperative peritoneal adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37799?source=related_link\">",
"      Superior mesenteric artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28070?source=related_link\">",
"      Surgery for recurrent epithelial ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/8/21642?source=related_link\">",
"      Treatment of small bowel neoplasms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_46_14059="Disorders with secondary mast cell activation";
var content_f13_46_14059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disease states associated with secondary mast cell activation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential mechanisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atopic diseases",
"       </td>",
"       <td>",
"        Allergen-specific IgE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic autoimmune urticaria",
"       </td>",
"       <td>",
"        Anti-IgE or anti-Fc&epsilon;RI autoantibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmunity",
"       </td>",
"       <td>",
"        IgG receptor, complement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic infections",
"       </td>",
"       <td>",
"        TLRs, IgG, complement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug allergy",
"       </td>",
"       <td>",
"        Specific receptors, complement, IgE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical stimuli",
"       </td>",
"       <td>",
"        Direct mast cell activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasms",
"       </td>",
"       <td>",
"        Complement, cytokines",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14059=[""].join("\n");
var outline_f13_46_14059=null;
var title_f13_46_14060="Quality of life measures";
var content_f13_46_14060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Urinary incontinence&ndash;specific quality of life measures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Target population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Measure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Women and men with UI",
"       </td>",
"       <td>",
"        I-QOL",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ICIQ",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women and men with overactive bladder",
"       </td>",
"       <td>",
"        OAB-q",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Women",
"       </td>",
"       <td>",
"        Incontinence Impact Questionnaire (IIQ) and Urogenital Distress Inventory (UDI), short forms",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kings Health Questionnaire",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CONTILIFE",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     UI: urinary incontinence; I-QOL: incontinence quality of life instrument; ICIQ: International Consultation on Incontinence Questionnaire; OAB-q: overactive bladder questionnaire.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Patrick DL, Martin ML, Bushnel DM, et al. Quality of life of women with urinary incontinence: Further development of the incontinence quality of life instrument (I-QOL). Urology 1999; 53:71.",
"      </li>",
"      <li>",
"       Avery K, Donovan J, Peters T, et al. ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004; 23:322.",
"      </li>",
"      <li>",
"       Coyne K, Revicki D, Hunt R, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res 2002; 11:563.",
"      </li>",
"      <li>",
"       Uebersax JS, Wyman JF, Shumaker SA, et al. Continence Program for Women Research Group. Short forms to assess life quality and symptom distress for urinary incontinence in women: The Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Neurourol Urodyn 1995; 14:131.",
"      </li>",
"      <li>",
"       Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. BJOG 1997; 104:1374.",
"      </li>",
"      <li>",
"       Amarenco G, Arnould B, Carita P, et al. European psychometric validation of the CONTILIFE: A quality of life questionnaire for urinary incontinence. Eur Urol 2003; 43:391.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14060=[""].join("\n");
var outline_f13_46_14060=null;
var title_f13_46_14061="Causes of neonatal pneumonia";
var content_f13_46_14061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common organisms associated with neonatal pneumonia according to route of acquisition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Transplacental",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rubella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adenovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mumps virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxoplasma gondii",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mycobacterium tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Treponema pallidum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Listeria monocytogenes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            At delivery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Group B streptococci",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Escherichia coli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Staphylococcus aureus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Klebsiella sp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other streptococci",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Haemophilus influenzae (nontypable)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Candida sp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlamydia tachomatis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ureaplasma urealyticum",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Amniotic fluid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Enteroviruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Genital mycoplasma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Listeria monocytogenes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlamydia trachomatis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mycobacterium tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Group B streptococci",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Escherichia coli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Haemophilus influenzae (nontypable)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ureaplasma urealyticum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Nosocomial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Staphylococcus aureus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Staphylococcus epidermidis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Group B streptococci",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Klebsiella sp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Enterobacter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pseudomonas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bacillus cereus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Citrobacter diversus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Influenza virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Respiratory synctial virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Enteroviruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Candida sp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspergillus sp",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14061=[""].join("\n");
var outline_f13_46_14061=null;
var title_f13_46_14062="Corkscrew esophagus barium swallow";
var content_f13_46_14062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corkscrew esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 202px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Esophagram performed in a 72-year-old man with intractable retrosternal pain and reflux shows marked spasm throughout the length of the esophagus, which produces a corkscrew-like appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14062=[""].join("\n");
var outline_f13_46_14062=null;
var title_f13_46_14063="Gram stain stool 1A with answer";
var content_f13_46_14063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Campylobacter jejuni in stool: Gram stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAXADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzZke2tzKzHy++eKyf7Rniv/tNs+5V7Gte9aO9RgGIT07Gs02ipt2gbB1FcSlbfc9GnGLXvI0IPFNwu5o7fc5HGTUYXUNUcyXQ2hj8q5pmmxwtfZxlUH3cd66Jrj7OiFFB5wOKE7O0VqZVeWnqkYsMLWlzskJXPYVtxvFEI1RssRyKj1xBHbxXcij5qrafPnLCPeegpLXUzl78bmqFMiY79qqTpKyiJiCp796tBJGY8445FSyQ5UYNNnPF2ZmR2si5G7P93NPYtGQG6H0q7tIb5gQq9M45prshUnGT6mp1ZpzXK2SpztBz6/pU3mSrjcMN2HaiQrhQ6KQeQDjk0vLklhgDNGwN3HI7xMWnYZduPapo0aWQh2IB6VWb94ArA/L0q1D2JOSfTtTJZeto3SPygQe+TSRSLJcMjjLxDINOglIyGH40oKKCVxvbvVIwZOxVsN6+9KwDDj86gZgIkLHnOSKl3LI2UzgDpQZ2sBIXAx170pBSM7Pwofj+lR7ig69e1MSEXeYyJAAPaoLhfk2McL3xVgzr5Z3HmqU0u9+BkE1LNIK+5GpTzsqpC097cM+UYkGp1gjaESiRFTGckgKB65ottl5DvtZMqPlLAfjQUxqDMfyqSV4AzSGJnwJDgVNJF5aDaSWzyaG3PxjA9RzTIuQX2mWt3F5UqtsPB2muTvNI1PTZSdOTz7VTnBPOK7WPJbacnHengkZAFK7W2ppTrOGhzmjyJqKtIrbJF++hPOa17aJI0LFcsepPNRf2baNefaQhSY9dvGatHcjFCMp/e9KTs9ipzTehl6nOkEaoqKzsSBmszybksXaPAPAArpPIiDb5ArN29qRhnkYC/wAqVkVGrZWRiwWzMM3I2v2wauLA6kGLkE455q4EQ8g5NNU7Scn6U7oiUm2IsOCC+ScetLKEIAXAxTJJwFI3UqyB4gfQc0bke8iqQ6N2NCysr88jsM4pJ58E1WGWPB596Rai2tTVU71IzgfWn24IfOKz4mZAOeTV62lbOB1NUrkSjYnu1laFzaxo02PlDuVXPucEj8jUZg2pyvOeDVjzCh2v370pcZAHPrVLyM9diugUtwOaSWJCq56+tO35f5U98Gm3LSMpAXFLzGlqMkQDB4+pqIwWtzAyXEccgPZlBpoZ0TbNyaZu2sGUYHvSuVY5EWrRQNMHJRRkqAf89qGDLA3nBQSTt2nnHb8amgZowIpc4Jp0sCuyZP8AFjmpWr1PX5rDtHUw3PzfOCuelbVs0fmMWX8DUUEMcXK9duKt2kCugeReOgpp31OWtO+5U1Q/bgQ+RCg6etSaSkaNuUL5e3jnpWheRYsysSjLcc1lGD7EYvNbKscGm9rERacbGvBlssMjmonl2yMjZJ7VTur+e3dLSzSIzSg7GdjhBx8xAByBkdxzgd+HySpBIiBSSF2j6AUr9TJQd7FmUNsHbPeqr5LL6DsKS2vYndwxIYdjVrygy8Hg96epduXci8sSyKTnKipfMLHaMYHWonZo8BATnvjpTlUp0796VtBMC/LFc/lT9gePaw3A9QR1pY2ch8xg4pY432BicE9hRYLk8UgXJfpinxyfPweCMjiq7KABuOW56U0y/Pjpj0oQmrl5YDIMkkZpI5GhkXJDLnBINSQTApgnmpCqE5bt1qrmOuzBp1Ayckt0px2/KXIyec+lUJmQ4PoeKax3xqVPJpXGoDrgh5Dt6VLBGChLDJqsjbOo9qvR4+Ucc0ki5aIxr263iS3VTtzj0p+kMYMJAvlwhiTjuT1J961riygMMoKku/f0NS28SQWiQBeAOfrVpq2gpTTQ2Q71xkYJ5NNjUIm0HAprxmI5UnGaGG5QwIYHuOlFjLQTzGRyVBI71LGwfJHBx0oXIQ9ASe9V53ZG+Xgjg0mPckbCOXJpryKiNuPGOKheViMHtVIpPJJ87AKOwqb3NIw7k7TFxjsKA7AYJ70RRqvU1O8abC2efSkN2RDJJhfl6iq9y5dWw3zU+4TYFAPFVH+8GHWkzSCRHDKZFIf76nH1omvNjLFDGzuepxwPwpC20kuOKVHG3MbZU9cDr9aLlyjfYZeE7CSD9QaIjjG7P1p8kfmRenPNLsAXDfnSK0sWLRlJAPHPHFaUVvGigqcHrWVaRlmJA+laiA7QWPPtWiOWroxzRZHLEgHNNEhzleoPepgxA+nanHG3OBkdKq+hlchGfMLDHPaiWUBefypgbJIz0OajeQN82M0rjsEzeaygcH1pGjBjK9D61FvAOeaGkV3w2ce9FkDuYVxZNGWyDvHTtiqVyksYXKkD1A6V0rQ723EnHof61I6xyxtGwBGMUr21OuNd9TKs4ZXtY5RuYk4NbUaYVVB4x0rK0lpLW5kt2UmI8jPar8rMk48s/L3qtU7GdV8zHzpmMtuJK8/Wq96VezwwG49M0t1K6wOFyZGGABVHT7CRgftk/wA5/h9KN9bhG0VdkMTfZmXdKGcjqetPklM8yqMszjGR2rWtre2Db/LyRxk1J5MaMGjCgn0qdLlusjPhso7ZRnLN3JrRWQC36dPbFAUEfOM0xowWC7uOlP1MnLm3I/MwCFHWnKp3YIIOPwpZIwgLE8KMmprZ2a2R2XbuB4o8wGqhA254PWpYskY9OKYAWPWpQo4wce9ICJQCGJNQyBcjB5HWrDAgEe/WomQOScfjmkUmMWfB5qR5225BxVaSL5uOfrUTgqMKCKVy7Jl1JQF+cA1LFsZVKnHtWSCxBHNP3SRqCvJ7CgTgau1SM56VKUJAIOAOlY9vdyPJsdce/atNGfb97GeRVpWM5qxZEjHAY96skHOQe1UYVZm+ckmpy5Ubc8079jJobO2QysfbAqrblm/dgkjPenorNISw4PXNMR/KwxGPWlctR0L0jbVIHBFUC5djnNK85OQep/Go0y3OMe9S3cqMLCsWCnHJqIDaDtGMkk/XvVLVtS+xy7E+Zj0rHTXZQzKy9c9T61PvPY6oYeUlc6PzCDzyO9NkkxjBP41irrSZAkU47GrhuN8SuisQfaldrcHQaepblnBX5jjAqm9yBnBBFPaLfgzN8p7dqy5UZI3WbaPmGMY6d+n6UJXFZR0LUUhdny4fJyAew9P51JZKyyyBnGGIKrjGBjpVW027QU4xwDV23iJk2THk8qRTsWmiZjt49aHUsvvUwtSAAxz6GntAwXg80JGTkkMsJFikG8ZzWkWyAV6Vz8wkSQMOma17OXzIV5wcVqlpc5au9y3GdxAJAz1J7VDZ3kN6khgLYU4O4Y69DRgg8mnQKiKUSNEXJJ2qBk+tBiPWMB2zzVZl2lhyB71JKHDkoevNRl9yZ5zUvuaxdiJWXo+KR5Id3y4PbNMDLkkiqMtzCpA2rwecevWnFXHKVi15xZeRz0qSJwiZ6HNV7aFvLIc5Oan8oNwOg68UabFkmFmzISFQDiojE72ziM4Y9CacIiYsEnGc1MowMDp7U0K423Xy4AC26TGN3vUSxIp3F2JBzj3qwxCqFxjPNMbAwB+dPqTuPXKpnH0BpyBGHoetIrtIQBkD1phDh23EEZ4x196S0DcnEmQcgAdKWRk4Ixx1OaiTkYyR6cdaSRFRPmbrQwsMngFwmJDhDwMU6SAuiwbyEUDB68D1pofMiwqOepPYCrTuMkccUr2KsQGUQSRqOQcLk024uGhuE3ECNuOe1OnjWSJsjkDII7VUldkiiWVd6n5Tn1qdGaximXjIG6HI9c0wsVyF6e9QRIUAXJxUkgkKgR8E9TSKsh9vIkpIBww7GntEWJ+UAVFFEqtu53Dv603c0cjNuZsn7uaOomrbDvJ5245qC4j2ZA9KteaDwFwe/NMZS5bcOB6igV2U7ZXBJbv+tXxk455quiBQeDTjIRgmm2FrkiyMJAd/QYwamFyMZLbjnHU1nySksdpqtBLJ5zIwOw8gipbuaKkmbLXDN8ykYFMkkDKCRVNpmRchS3tT4JWkPzAqetAuSxZQbwTwTTwwRCOtMQEpzxUNxcpBEZJeFFFxKN2YurW80t0zwrurnp0dWYFSpziuon1hMZgiJ3dTnpWIzC4kcs4IDZwKIt9UenRbS1KSg7EUq+8nCmtbUJ59OhigbKgjOT3qfTYFMqByNq8/MOlWNcjF1tLnzBjqKJO7SsKU05WOeTWLi3YLKMoT1q+s0d6UVWyCfXOKzrqwfJUI+z1PaqEKSwSN5THCHrmr0e25nUoqp8J3dpZqq8dqvKoUKCORXOaPrqjalwPxro45I5/nicFal3TszhlSlDckZ+hNP3jb7VBs3OVzj1pGyo7/AJ000ZMcyox5x6fSqsoaN8pxinAsSxz06VIHUAEpvIHT1qluS1Ymgk3gFl+YDGM9qmDA9D9RTFj3MshBXjpmkeDJcjIJ5OOM09DFkjOUJBHI96btIiJI4NNTiML0wMDJzTt7bCpOaT2LRVMAYNhgKy5rWMybS5z3rYUMZACPl71KLaF28xQBnjkUlcJWvqZXnsq7T3qzC5MfykZ9DRJGCuSQG6DIz+lVt2GIJH4UWNC7JK6RKUTce4otJnZiWRk/2T1qOFl2AgnFTK3OVPXrTXYGtAa4VnC4wccUEBRuYZpWgDHdkj1pk0qQozyH5FHJ/If1p37CsToORxgHrUyBTkkCqcE5khWWPmNhkH8cf0pWl28k5J7UmK1y24DDIAIHeomwWyen51F5/AAGARSEnbk8GgaQ+OII7kck9/amSxndtD4J71Imdue9OEZJ3HGR0ouMg+zSbsecdvcUstqCAC5ODkZq2qqMHALdPpUZVt3QkZo1K5xAgC80uzcMKKfHHuJJOF9qmACocdamwc5VVWHBXrUcp28kY+lTSXixSgSDAboSOKW4XzBkcjFJq2rLT1KBkweSPwqL7W24g9PWlmUhiccjmqXzSNxSSvudCimaAkU4PJ+lRSzopAbgZ70/To1aTy2brTb+zaGQkglCeDVW1sRomMJRydhB5xUiR9CB+lU2h2kEcHsRV2DcQO9JxtqU2uhLsA464pRwxxnnin7Mg+pFIqjGSfyqSGyOW72fKo+cdu1ZupSu1i7Sqchs+1aGP3udue1Q6pEbiyeOP72fzoa2NKckpHJ3N+ZUREQqAOfepdOdAy4XgHp61am0udlDmMkKMU22tzGiqqEOW5q0layPQc4tFk3AE0axDcWOGAFbsdpIipvXcmOg7Gqen2rxXG7Z8p/M1dlnkSMqrbnJwPah7JI8+rK8vdMy4hzDIYy2Qec1z91bKLkfMdjda6y6wjkDliOTWK0PmxMwxiMk5qU9bnRRloZl/bRWewRdTg1r6JM6TgA/KyjIrHupjcMokHC8Zrd8P2+yIynndwAfStFF8vvDxM4qBsQlnmO3k1YaF0XAFTQIkYBUcmnSSZNNI8SVTXQzJAybsrgA5HFRWckZkdwW3d+K02G8Ej8aqTmNJMMAuR371PU0jLmRY8ySRNy/cqyoYDOM+tRWW3GwZUdqsAiM4YhvcVT0Rk97IY8ZYHAGT0NV2hZQAuPxFXDINuVGTTGDOueh9KFoCZWIIYrnGKnUYUbehqMxAqS/Uimpujg7ccUdBsz3ffj19zzSBVJbPNQv04z6c0+I4Gd34VPQ6LEq7hwvAHapUYY4OarFyQDipN4UEg/N2pBYnMoX7zYHuaY+2SGaJuUlQrn0z0P4HBqrPALlAHJBHof0qzGFACjoB3oK5dCOxhe1tVh3A7SSOfXHH55/OpgGOd1DEK2MnP1pd7ErtYYzzmi5NhwjwKXZuHWm7jv+8Kdkg4B61RNiaJcDB9KfuC9TmoslahkZiRt2ge9LcRf3AY54NBkByV4qhHJxlqkMrEDac9qdiWXEUsNw5FKVPvyaSGfEYUcmniUFnBz8voKA1EWJcfOob61HJLgkKParBOQQRgVAYVA3iotctPuUZoiUJOC1ZhXb0Jz3rekgGxmz1qjPbcnnPpSWh005ozbYv9sjGQDnIGeorpJpPMt2QrncMVlR2375ZMfOOhz+Fa9uy7Pm7etOT0Cau7oyDEqY3cY7GnRSL0XHHpSXZ8+eRs8AVXtoyVOCCw9KHruaKOheWYM2MUrtgg54NV4QysQatFQY1BGDQ0YzViuCM89fWnlgDwfalRF3H+VO8rByOtGhN2NQ5XDHg+9LO0IVG2phTzjrTzCrnkYBqJ9PikhMYBAPU5oSV7lKXcv5QcpjAH6VzOr3yJdAxYDZ6g8fSr98Z7HTiVJcqcA47Vyjs0shZlxzkNQotu/Q3oU09WbjPNcuqxOAWHX0rRgsYoo1RuSfvfWsfQ2c3iMmWAGK15S81xwpRF689aduX3SazalZDm0yzVxKUXP0qdNu3EYGB6VDOTgZbgcYHepLcqAcnj6015s46km1qSbyh+alRyw6HFOk8vHygGo0Of8AV5HsRiqMLD43WRioJAB54qi1lK2prJM26BfmAFaccKIxZVAZuWIHWlaItzuwKOt0VGXLsShh5WUAIqNs/eGee1NB2fID8velL4IAxiglIJN20471FbysuUkbvVvaW5zxUDxhSSw5PehAvMc5DMOeKc6q0eP61FsXHBOTUdpOks0sLRENHj5z3ot2B9zMOFQHBY1Va3dJfMhJyT90nirRBAAoXk8546VKdjsQ9GwoyOcc0nBOe3tQp3dj+NKPQjNIBC+1fWmeYxfCjAp0gJI5yKVBtYEDjvSKXmBLBeadATk46CpNgI5xu9Kjb5ZhgdqZDZLsyAcnmpY0bcpBGO+aYkqltrEZzUeo3kdhbl3+92ApOXYIwcnZFybaFyxx2qhcXkSEZkTBrl7/AFx5mbc+0D+EGqtxcebAGVyxx0NFpdTqWEtudWl+kkgCMGA7iplu4zNgMp/GvPTcTDcYi4Xvin2txIG3F2J+tX7NrqS8MmenwFTjGavwEZI6f1rjtD1MyERSsdx6HNdZbOCeenfNF+jOOpScGWimfunOOtR9Q2RwKnXHl5HQ1AwITgYPrSsQmIEJHSopFLAluKspnYCetQ5yx3DoOtJouLZEEVVyTwRUm0GIgHtQu09Rx0FOkXHKjilYvmdzEniJZhyPoaS0RYWzlsZzzWrLEHOehpkMKMeo/pTvob+00K4IlmyRgDpVopx0zQIlRgBUzKSOBR6GUpXKjqR1GBSxtg/Wp54GZ/MzxjG3Ht/k0gUbuB09aRN7oaVIORikBzn2qdHUAqcHFRyKe34Ugv3FVlkRlIBU8EGsy5062SNtyfJn+H1NWWYxZPpSPOhX5nXB7Gi3Yaco7EVvBBBCvkDAIznvVfy5mdpHztB+Va0gqsmcgj0ph29PSqQudmakkjbt6bcHj3qZELIexqV0yegx/KmhivTH0ovrcl6k0SBEGevvUyxgLnNQhw+NtTKfwFO5m4kpcYwTTA5zimgEk8Zz2pCGU4IouKw/bxnqKIdr7getM35GATUbvtPBwc0kx8uhaabylxnOKryXSZA6nvUE8owAhJb1pltbmQgkGqV2KySuzQhzjJ5+tOOBnoCaeke1AvpxVOeYJKM52g9qqxktTOZiCAP1oPTt9aiuXSNGd2CRoMlmPAFPi2yKHVg6MMgqcg1md4biv1xinSHgc9R+dJJuC4QDf0pILQ7leVifbNHmMUK24bcbOc565qYISBkfkKcNofGKmGRgcbcdc0IhshQEtx1pkkZLHPGeMirBQbs1E/MwznGcjHegkbDapEwcHJ681zHiSeSe73DPlJ8uMVv3N0Vm2RgnHrRf2kc9lJLIvzAZpXs+ZnXQfJLU4NnRwVEYJJ7inuD5qqBggYIFXo9jxPhAuGwPemG2drgHop6VpezPSk00PskXBAAyfaqs9o4nYouEq7b2bpdPhWx610FgAkI3qpI9RRezujinPkOasplRxyd2eMCuz0O7knbDJlSPvUv9kWd4A7xbWHQitG3tlsoxHEp2+1Ds9lqc9StGasXDNtQKMU6OQSdAOtQyL5bAuQM0+JcfMvAz+FQcrRJIWAAQj6Ux1JODxx1qK3eaRpTInlhDgHn/ADn6VMZFPGcsKGCRH5ZAyRmpVO4EHtTQ/HUZpokC8rjrzRdDabHyAtG3FU1gkFwmF/dkctjvV0SCQegp2wOQKEF2tCHy+Oaeqv5qqq/L1JqSQFdoHQU9GCsGPPNMRXll8tW3dMVHtWROWwPan3S+exUD5TVS5WSOLZbjLcAfTvSSuytEixFDGkYMY4z1pkgOeO1SDd5CKxwwAzj1qF5FUbTgnvmm9SExjDCgk/8A16rskbSbmQFj0pZHOD1wKarbm2jHrmp2NE2SAhFwcLnoBUc8mBwOlRtmYHHQVEysG56D3oCxOhJXIxg00oxJwBUqDEYzz+FBIABpXBCRoVOfWp3yE461EpCuSOaa0pJHAx3PvTbFbUhlupUIWGPv17Uq3Mh/13HHXHFKTgc+lVbnLAA56+lK5aSY9rxM7QxJzgYFOikZmIzkVUjRRlm2qigkljjApui3tvqD3D2Vwk0cRCsV4wf6imu6HKKsbCxjbnvV+2ZPL4HTviqCSFQRipopDtwBVx2OSoi0zjBxWfIGLOSBtFLcTTYxCoLE85x/WgFiGUDkgFvSm7kJWMy4CeWVlUFW4IPeljVY40WMIiKOAowBSTQG4cYyAKilXfIqRscr1NZnoJIn34O4ZpbW5WRirZU5zzVZBIFIfqOnvUCSSJcrIF78inZsrlRtIVZs5GadMxAHPQ/hTLZI3AdmySafcxqI8cHJoRi1ZlV7lcld2DnAphkdJA3Vm4ANSS2xcZ+UEdDikEYVg0nLrxTHoLHab5N8rZJ9Kg8QyJp9nhXJaQbcE1pWboXyxAB5xWV44tftMNtJbkb42/SjRyUZFUpe/qYEKLuRShAwCCanlZIcORuQc1UhM9vclLp8qBwM0XkgkchSdmOlL7R7DhdaGza3UUjYBxkdavRROTiNWc+1c/p8qrJyh3AfpWsFbUNMaK3mMBZgxJzggZ+Xjnrg/hRs/I4KtNo6uBAIQD1xzSTOUKoVJ3Hlx0Xjqf8A63+NZ+nXMcMccAMkjooUserHHJ9smppJHdQzjaCeh9Kcm0cSp6il0UF5ST6AmpLe+SeNkTCsD93NZdy2ZCAw/Gq1mwExK4z0BrPmTOn2GlzWlvXMojTeM/Lk9B/n+lSLLDBBJmQM6j8/pULLJKMBcgjGazLuxNrGGMu7LdD2oeugoU4t2L+m3akMZckH9K0otk3zIcj0rnS3lwkr1qxZ3MsBQuCFPqOtNXeqLqUVujoYkAGAOKniwoO4ZOO9U7e4SaMMDz1PNTFuAyVUX1OOaadmXYBH5bGU84+WqFwQTx09qeWZlAx+FQyggk96p6kp2ERiG4p6t8/zDOKE+VSeuPWo3JGM/lS6ibuRXbGMM65bHIA6mqscnnsHKleT3qS5O7B6EVWinDOQxoKS0FuJ41UgDPY1DCN6KQSpNSGNZDnAGTT4XVXaMg4WhpLYpbEjAJFwecVAIyxzzU24MOKf0THpUhsRkYUD26VNGisgzULrnAJ4PapI8hcA0CY+SAEjaciq0sTKc5x7Va3EDIz+VMZsg7qBJlXGV549qgcAtjNXJFwBt4quY/nz+VJlxYyS2hubaWCYExyoVbHFQ6Bo1po9vJDYo2JWy7ucs2Ogq3EuDx1FXYFVevBqo32JnIQoq444pQqoxOSQR0ptyf4QTUIkwQpxiqiYNtlqPZktnB7A0kh3cZwTTlj2/MD29KYVywIOSKpkXMiC6V0VEB3DqcdKsBI1QHkHOc1mWE/lzmNgOe5rWj2lP3hB9Kzsk7HoT02CMKDkckiomTcSNuD2xTg6FyQOB0xVhTEUzxx0ptIjmaKsA8osRjrVgSkg7k47VBJLDEWLuOO2ajF5Gi7zyG4FJj5Wyx5+SUxgrTyAwBP54rJXcbh9mSucls1rxSRugA4PSi1iZq2xWuEKkbVyaFXzgQ+M4xir7xK6jJPNQ21vEjuUOSe570PVCjLqcpf6VLFcFnz5R5z6VUFpkCQE+WeBmu/aONhhuRUHkwhjtiX6Yp82h2QxbSszkbXEeAcnnGMVtQafdbUkjChPStLy4VbiJAc9cVctnCwlm5QU3JJXsZVMRKWxTtliwXciN16npWTqGsNK2y2CttyKzfE2qrc36x2LkRBcMy9Cap2SMuSpyCOTWfLpzS+46qNGy5mWXuZXlbzuT3xSRTNE6uowAeagG6GUll3ZFPQFhub06CqsdSs1ZnV/aw9ojQuM45x2qMKk8TGd+V6VzKm5tmRikiL1Ge4rdi/fIjrnB61HK1pc5ZQUdUQxu6zAMMqOlX7i4aeFUYAMOQQKT7OxAK/eoiszFbKGdnKjlj1Y07J6kuaIYLh7d8jBVjyPWujspUlRWXlPSsKPYVywyo9alsbvyJymMI36U+pjWjzrQ3yVRyf4T0qKaaOR2jU/MBk00OGQYOQeaNq7SQoye9VvqcNrA2DF16VE3zYNOdtsBJX8v8+9QfNsDDODQBBM/wA+ce1UwpZ2GMe9W/ODPtApZAAwZVGTTWhexHCJMlAuQepqQrtyWppd0w3PI5xUcshbhjjND1GiRDukIxwOlBc7iKSFWjUng57VBIx8zpgGpe4XJZHBXg59Kkhk4ANVSxxTRMQ3WpuNI0fMAXFIx39BVeJ9x55/rU5yUI5oExVTP3j7imycemB3p0e1cLye+aV8EUNgiFeDmra4MXyjJqCFMtg//qq8gGMKuBVpaGVR6mfKpH3iR70LCqAMSS2KsXkaSLsYdTxSy4jCgdQKaslcjV6DDIwUjHXjOKfAhCksc571Xj3OCdvTvU0bskWCKYmuiMCO2Ta5fBZe4p6nC+YpIHvVNL0SLtBAU9ST1pxuiECkjBPFZ3Z6TgW45xtO8bffvVOW6dYSyOBlsAEU4oHUNK5HpxSXUEYgLqSGU5HvQn3ElFEMTtK0oZQ2RjJFEKTTIuR+7XpRaO80wVVCg/erZtxGg9+9O9mVKXKiAExptAxnsO9EbMQCSCOtWGw0gJG38aeEBDsRnHP1prQ53K5ZhkLR5YflTcYPGPelt5UVOenvQJV835SSKV+xNtRYWPIf8KfgMM5I4qndvKIiyDGDTwJ54VkLKoPQDmldl8g2WZVL+YjADkH1qjqep7NLlGxk3cAN3q/DHJIrJPgr24rE8SQPJIkYfhQMZptJuzNqEU5HPxQgW4weSc89qu2zFQRG2Nw5qGJsqYiu7HerttCqgHAyelOV3uek2loPKKYhvyzdBxVmEW9sjSzEGRTlUqEIyMEPJzUt3bIYgT8zg81D7XIumV9U1G41LYdoEadMDpVnTrwwBVfDJnk9SKz5EaNNsRyOpqxYNE0Tb/vHpRZJWS0Lmly2OgeaQuvkISD0xV+OVks2EicgcCqOjwfZkMsjfL2BNPubkDqdsZPU9xRbSyPNnq9Cj9p2KyleWPeqkkzB+BuYjA+lWZY1nkBj79Kvx6fFFGGkG5/c9Kei1Zq5qKsXdJO62/ecEL0NWgyrwM81QhVlx82AOg9asBhu5PNO5xTSbuPIwSD3pAflJOfShjtGSRmhDlTj+dFyLERt0C7lHNLFExwGxQzlE+XB+tAl3kBR9fSncmwGJB94GmS2+85Xip2YMQGIH41BMXCfumXPHU0r3Y9SF0Knk/Sq7kM4GOh9KvSAhcNy54NVGUbwc809BXIZcDPp61B94+1Wp1DjOOfSoEQqcnBJqWaxZPCxT3xVmNxsyetVR15pS+PrUlWuS5y5J70/cOc1FG4Yjrn6U9cYyc5NFwsWYWGP8anZwBxyaqocDuKtRgZ3EHArRaowmtSnL58sgAABFSz5dkGO3XNWE2szMoPtUcyGRcLwRVWRnfUbbJgMDTmBwcgAZ4qJC8YZXGffNKNzgFsDvxQSzjYbIkFmOMkkClhtJnLMSdo6ZqfftfaTu9CPSrVncRYZHbvS5mepKOhD5cp+VuuOtNmiYxEOePfvV+SZHcLH1HTFVrnaUKthmJxjFK72M4x1uU9IlRYn2kF93X1rSSbYASMYODUE9ogVfJTaScse5pYYgeBk44zUuSbuW4XLMk29cjr7dqeJhHGcvz6VUigIyxb5T2FWYoiEwqBvqKaszNxsSWzPL823anoauxkKRnrUFsZMtvCj09qnSBc7i2SP0oZm2PZAUIPIPb1psI8tdmMrngelKz8EHGemKaCd53HOelIaHxj96c8Z96qa5aJdRAK22UDjjrVptwDFep6GlsnD26tIBuBxVX6lJuPvI5u2shbzKCC59AOKvQabI0ckj4RQSQMdRWx5abCfl6+lJPKViYAZQjn3pSfY09rJswGv4hEwkjAbs1ZlzeCQlYT8vc07V9PupwxgUCMnPXpVGwt3jxvUFV5OaXJH4rnpUrWLsW14WPf0qxYxeYyfKQSMHHaq9vGCuVbljkKB0roNMtBaw+acl2HNFrGdaokrEhZo0CklVHr3NSmITbRL0qFoRJKrSk46haluWcR/ugpY8CltscL1YlsgSRscqOmKuO4bAOCR2rItDdx3BVwNhHUetaIwCTg5A5OKbTuTJEnmENikcgybuSQaruec9M0IxA5PFIVi28+44wMe3SljIwcE9apNJ279aA5J/nQvIlxJRMWvHjbhQufrU5XCfKc96qjaJWY9TUyscY9expkvTYiwzudxO6rMW9FLAngdKgQfvGLVYil+Ur/Sm9gepVkuCwY7Hb0x0NRwpIyZkG0n86utMBx/SgENyR1PpQmiWVwm3AxTpIcL0q4ApAJHTvQQsp+Rc49RRYnmKCRHGeaikt/mLAnpWnLGVAyOtMVRj5hxS5WUqiRQRD0Gal8tsfKT+NXBGn405kwAFPNPlD2hHDGSxx+lXYwFHPNOhRAi7evvS7Rk56Z4qjCcrsqGTBIU45pm/Zu5Jqaa3yBjOfpUQjAOwDJ9adhXRXEhZxx1q0B8p4NMmhEfzAc1HHKe4/8ArUgavqc3aW3nRvITtA7VUjjJufL4AJ49a1hYmHbKkp2nqKpyutveecVzg0uazdtT1I+8Wri3a2RGwQ54ye9QJAIi0rNmQ8gGp7q5eYB2GE7VVacuwGcACpUnYagTyyNgbpBnHNOifdHgEAfzrNvZi23ymCYPPON1bmh2ef30qjB+6CMU0tLsVRKEbklpbO65cYHYetXVj28AcVZRSHPGTikkKxYDDlv0q7WPPlNyZX8rnjnNM28kA/rUyupU7z2qCN/MmYAfKKVrlJ9xNgYkHoaV9kbIrModzhASASQCePXgE/hVxbcsueg9aUW5IwT0o5Q9okZzMyuQT0pkBEO/BJVjn6VoSW+3LMOvSqjRAdulTymkaiZFZv5sryMf3Y4AqS5ePyn2nOBxUYhC/dFRCItIwZiVPbmhmmjYltG8sWd341m6hp0sPywfOHq7NNcJdJHAPkxzUkLuk4WRySRSV07m8ZuC0YaXYeRal3UFmGB7VdOMqpb7uAaFuGQEAgjH5VWhlMZxJlhjGT1+pp6vUybcnqWSASFyPSoJtyOAMFc4zU6SowLZ2qegNRM2xgD0zmkldiJVj2gEdM55FKeFz1qxJgx4X06VDJwoCml0uSndlbDEZ4PvTCvX3qRsqAO31prkAnHGaC0QMwB69KFc5IHXNDHLDoMcUmMNnOKAZIZSOeOOKkjkJXnuaq4PJJx9KUSYXGaCHG5ciYlsLmpc9ARyaq28uG5NWQ4K5HOKozkmhpUljzxVq3XKB+vFQx8gn3rQt3UxLgU0jOcgSPKA8fnSm5hh3Rs6q6jJDHFSKwAGMD6VwPjyZW1qG0Gd8u3OwnK+g+v9KN3YKNNVG0zufMSQAqytkdqjK8nPQ1xMLTWDRxW1y0oRQuc5z6/rmui0LVDfrKk+Flj9D1oi+vQuthnTV0XnQllIbaM8/wD1qpm4mWRtq7znGKvnBOc8VTnVUbKZB71okcykW0nMaBm7dasLOW2gYweaymkBXHUe9LFKRwxpMm9zb8xRy5xk4qtdErnHGaoXVy4iCwtmQ+laEBH2fMh3MRzU20uWtCBpDIgVATtHNNVW8rJGDUyuAdoAWoppAV2dxzQBzB1AXEIjjYBQe/Ws7VHGBhvmz25qaKxsxGxLuZB79auh7Vbc7YlDqMN65x3qE0npc9myjsX9N0641PT4XDLDFt4yMk1DP4XvEEkn2pWA7YrV8L3QudIj2kZjJBA7c1pSEE4DEr35rWDaukedUrTjMxrDSLf7PCs8IZ05z71rbBjKjAHSnREAnnAHSllYKmQT9KOpjOpKW4x7hYsO59jVWe6F24SEbVX171Uvl8xw3O3vzU1paswDJnjgmjl6scbJBGjMWDYweAKvx26RDKqOnNUQyWcpa8baueNq7v0FaZkiaEOrDaec1TIkyXOBkjtmohKGPTKnvQrbkznIquZkBCD5QOc1IlEsXBxHz3IFV5bffGdoySOQak4UhmfHpThKqk45PejQE2jPZGUfPj6UvkggMB15qa4Yuu4HrxVa4lljjzHy/TGKT8jaLuE0KqN4PzDjOaqDIlDY5HGcU24ugh8uZsSAZIHaoU1GOUqkKMzHg8cdu4PFZ69TrimkaMiL8vAyaY48ptgGQajl4OR1FVorwm/EfBcjO2kkHK3qi5Lb/MCzc9hT5VRoAf4ycLVe4uGZ1WTAJOBzVyGCRifLXIA59q0V2ZTbjuSQlli/edaArP06GpFwFCkZOetKoaMkBck0WvsZcxVgHnSyxOm10OTn06U6W22/Nj86e8MplEsRKyDqMkZ/Grk6SyIMgUOIvaGJLCACwqBzyBWtcqojIxhh2FZzQspORUtG0ZleRgMcZJprkrjGeeOBUrAE85Hfio+/HBNSaEZG5wNxGOfrVq3kwwXPtUDKTgn9KjywO/jg4FF0DjdG5H8vTG01Pbn5XUcAVlw3W0qHwfatCzmWQkqRgmrizkqQaLGJChEL7ZP4W9K53V9AKwfbEfzb0HJYjgDPIHvjvXToV3HtmnbgQQe/aqfkRTqOnK6PM1uysxYAI3oRWh4daWbVmcDOV59K6u70nT7tszW6k+o60sFhb2Ee21TaD1Jqo8sbtI7KuLVSHLYaxOAD1qvI3rVl8Kck81l3cz79qLnNWux5rWtx7nIyP1qPztvc4qFNxcbjillPy8849KmSWw1cuW77ZAUHWr0dxtyrDjr1rGst5yc8VowoRtc8kCoZa8y1xzjv0poTIORikVskLjBppd/uMMnqTSKRyjheeMDrzSnkjJOPQ0jneSdueOTio5plSInJwOuATx+FQe2iTSbiTTtZ8tZMQTdRnjNdxhnZEx+5YfM2PXPft9O9ec30Ui263IGFV+CK7/Tnd7KKRxyyitL7S+X3HBjYJaosCEMhKsTj+dSIEaAIRn+dIckkdqa2ImGfxxV2PPuxoRDlSoITk+9Ldy+UA6jAzyBSK2GJweeeKbKvm8ZAA65pWKuxrTW1xhZkjfHOJF3VMiRsBjGzHAUVWtbNAvmXLgtjBxwM1J5ghdTy6kZBAOMfXp+FO1tguugrHyCeuD0qIAOCT949KmmxLtZ8Y60ibPNHHyjr70rXKT0EBG3a3IFSrsAG08HpRKwXGcEdqryEsh8vAx0zQTuOEZKyBgRg8GnorEAsBxSkkxp8w3Y5HrT3ZVAQkBj3pbju0ZmraWlx+/gbbMOoHesu2KrbvmIeeh5JUA/yrXvLh4LZ3U8duOpqlEv9pQExlIpwOuetRJO2ux20amlmJBKblA2frU1tYoLlpyu2QjAPfFUrWN7WQK+SM84HFWb6/wDKQeSru3ThaajLaPUuTT0RBMjx6mgdSyqCc+9bEF9FvMbEKw96yYJZt2brgY4BHNLPcW8E+XUGQjinJ2WqMpR53Y3VMbv8hBqdFAkBHI9xXEJq8ltdO8JyvdT6V1ukXiXtss0fbgj3oTZnWoSpq5oIQSeMe5p3XuPwqB3fHzDA7YoyN2R1qrHKQ3iBW3dRUccccq/dGasXAZkwBx3qBdsagZHPWk0aJ6GfcQYcgdBVNV5OR04rfWOMR5PJNZEyhJG+tQ1Y6KU76FWbPy7VGScHnGB6+9VLwTHakGVOeWzirsuAQB6elRsCTz0rO50JEADqF3Ek+vrVi2maMjaDj0pCpJBPapY48sOOtUiJ2NBLo/LjJNTLMGYg/LVQxhCp6rSzRvsBUgH164rRWOSUV0LuGXkNkHpTGkYtsPT1qEXJ2KCOe/FO38ZAp79DNKxHcQsdpJIGeR7VGUSRdwXGKtRlpdwNP8pVUBRz3xVLYJGTJbnO7k5qvK7R5GzdmtiQrjcQcDnpVeSJHK42nnrU3EkZ6FtoAGCe1aNs4DBTTJIwP4PyqKeB5IMxOUcEEHFK99x2RpEKnPU+tQupHz5HNOjLNEN/JAxmklkUqQBge9N6iV0f/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of stool (x1000) can, in some cases, show Campylobacter jejuni, which are small, faint Gram negative curved rods which may be gull-winged in shape. This finding may provide presumptive evidence of Campylobacter infection prior to the results of stool culture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_46_14063=[""].join("\n");
var outline_f13_46_14063=null;
